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Abstract

Mechanism of Action and Gold Nanoparticle Delivery of Pt(IV) Prodrugs of Cisplatin

Yi Shi
Syracuse University, December 2012

The antitumor effects of platinum(IV) complexes, considered prodrugs for cisplatin, are
believed to be due to biological reduction of Pt(IV) to Pt(II), with the reduction products binding
to DNA and other cellular targets. In this work we used pBR322 DNA to capture the products of
reduction of oxoplatin, c,t,c-[PtCl2(OH)2(NH3)2], 2, and a carboxylate-modified analog, c,t,c[PtCl2(OH)(O2CCH2CH2CO2H)(NH3)2], 3, by ascorbic acid (AsA) or glutathione (GSH). Since
carbonate plays a significant role in the speciation of platinum complexes in solution, we also
investigated the effects of carbonate on the reduction/DNA-binding process. In pH 7.4 buffer in
the absence of carbonate, both 2 and 3 are reduced by AsA to cisplatin (confirmed using 195Pt
NMR), which binds to and unwinds closed circular DNA in a manner consistent with the
formation of the well-known 1, 2 intrastrand DNA crosslink. However, when GSH is used as the
reducing agent for 2 and 3, 195Pt NMR shows that cisplatin is not produced in the reaction
medium. Although the Pt(II) products bind to closed circular DNA, their effect on the mobility
of Form I DNA is different from that produced by cisplatin. When physiological carbonate is
present in the reduction medium, 13C NMR shows that Pt(II) carbonato complexes form which
block or impede platinum binding to DNA. Another Pt(IV) complex, 1-adamantanemethylaminePt(IV), 4, which is also a potential prodrug of cisplatin was synthesized by tethering 1-

adamantanemethylamine to oxoplatin using a dicarboxylate linker. To achieve higher anticancer
activity and better targeting, gold nanoparticle (AuNP) coated with the host ligand per-6-thio-βcyclodextrin, was synthesized as a drug delivery vehicle for complex 4. The results of
cytotoxicity studies show that the loaded delivery vehicle inhibits the growth of human
neuroblastoma cells and optical microscopy indicates that the nanoparticles localize in the
nucleus of the cell. The binding of complex 4 and β-cyclodextrin is also investigated using 1H
NMR, and a model with a 1:1 stoichiometry with formation of adamantane dimers is proposed.
To achieve better understanding of the effect of recovery time on cell cytotoxicity, the toxic
effects of three metal complexes containing the 2,2'-bypyridine ligand, Cu(bpy)(NCS)2, 8,
[Cu(bpy)2(H2O)](PF6)2, 9, and Zn(bpy)2(NCS)3, 10, were investigated toward human
neuroblastoma cells (SK-N-SH) and ovarian cancer cells (OVCAR-3) using two different
cytotoxicity assays. The cells were exposed to various concentrations of the compounds for 1 h
and the percent inhibition of cell growth, I, measured for various times after exposure, i.e., as a
function of the recovery time t. After developing the theory showing the relationship between I
and t, the cytotoxicity data were analyzed to reveal that the two copper complexes, 8 and 9, cause
the cells to divide at a slower rate than the controls during the recovery period, but the zinc
complex, 10, had little or no effect on cell division during the recovery period. The usual metric
for reporting cytotoxicity is IC50, which is the concentration of agent required to inhibit cell
growth to 50% of the control population. However, since IC50 can depend on the recovery time,
t, as is the case for 8 and 9, reporting IC50 for a single recovery time can hide important
information about the long-time effects of a cytotoxic agent on the health of the cell population.
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1. Introduction
Metallic elements play essential roles in biological systems due to their unique properties.
Metal atoms lose electrons easily to form cations which are soluble in biological fluids, and can
act as charge carriers, e.g. sodium-potassium pump, and bind with electron rich biological
molecules such as proteins and DNA along with small molecules crucial to life such as O2. The
positively charged metal ions are able to control catalysis processes by modifying electron flow
in a substrate or enzyme and multivalent metal ions can provide sites for redox activities.
Although inorganic compounds with metals have been used in the medical field since up to 5000
years ago when Egyptians used copper to sterilize water (3000 BC) and gold was used in a
variety of medicines in China (2500 BC), medicinal inorganic chemistry emerged as a discipline
just about 40 years ago, since the discovery of the antitumor activity of cisplatin.1
The small molecule drug cis-diamminedichloroplatinum(II), cisplatin (Figure 1-1), is
renowned for a high level and broad spectrum of anticancer activity. Cisplatin was first
synthesized by Michele Peyrone in 1845 and known as Peyrone’s chloride thereafter.2 In 1890s,
Alfred Werner proposed the square planer configuration of cisplatin, distinguishing cisplatin
from its trans stereoisomer transplatin, trans-[PtCl2(NH3)2], and the study was a foundation of
Alfred Werner’s theory of coordination chemistry for which he won the Nobel Prize in 1913.2 To
improve the purity of cisplatin and reaction yield, Dhar published “A rapid method for the
synthesis of cis-[PtCl2(NH3)2]”, which many subsequent cisplatin synthesis methods were based
on. The procedure was dependent on the trans effect, first introduced by Chernyaev in 1926
which elucidate that the rate of substitution of a ligand in a square planar or octahedral metal
complex is dependent on the nature of group opposite to it.2
1

Figure 1-1. Structures of Pt(II) and Pt(IV) anticancer drugs.

The antitumor activity of cisplatin was discovered by Rosenberg and coworkers in 1960s,
when they were examining whether electrical currents affect cellular division.3,4 The researchers
found that the inhibition of cellular division observed in the study was not due to electrical
current but platinum hydrolysis products formed from platinum electrodes. After testing a group
of various Pt(II) and Pt(IV) compounds, they reported that cistetrachlorodiammineplatinum(IV), cis- [PtCl4(NH3)2] (Figure 1-1), was the potent agent
responsible for the inhibition while the trans form of the Pt(IV) complex was found to be
ineffective.3 The researchers further tested cis- [PtCl4(NH3)2], its Pt(II) analog, later to be named
cisplatin and other neutral platinum complexes against Sarcoma 180 tumors in Swiss white mice
to find again that the cis-configurations were active while the corresponding trans-configurations
were not active. The large solid tumors were shrunk by the cis forms of the complexes and the
mice survived the cancer and became healthy. Cisplatin has been tested against a large number of
various animal tumors and was the first platinum drug chosen by National Cancer Institute to be
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entered into clinical trials. The complex ultimately succeeded in clinical trials and was approved
by the U.S. Food and Drug Administration (FDA) in 1978 under the name of Platinol® for use in
humans to treat conditions such as testicular and ovarian cancers and ultimately obtained worldwide approval.5
It is widely accepted that nuclear DNA is a crucial biological target of cisplatin along
with other targets such as RNA, enzymes containing sulfur and mitochondria6,7. Cisplatin enters
cancer cells through passive diffusion and active transport mechanisms.8,9 Inside cancer cells the
chloride concentration is relatively low so that one of the chloride ligands is substituted by the
oxygen on a water molecule, forming a positive charged species of which the water ligand can be
further replaced by N-7 of a guanine or adenine on DNA to form a monofunctional DNA adduct
and the second chloride ion on cisplatin can either be replaced directly by N-7 of an adjacent
guanine/adenine or firstly be aquated and then replaced by N-7 of an adjacent guanine or
adenine. Approximately 65% of the bifunctional adducts are GpG, and 25% are ApG.10 The
intrastrand coordination bonds between Pt(II) and DNA bases cause distortions of DNA strand
and thus inhibit DNA replications and lead to cell death.
The research of producing platinum-based anticancer compounds is continuing after the
discovery of anticancer activity of cisplatin. The second-generation drug, carboplatin
(diamine[1,1-cyclobutanedicarboxylato(2-)]-O,O’-platinum(II)) (Figure 1-1) with fewer side
effects was the second to enter US market as Paraplatin® in 1989 and became approved worldwide to be used in cancer chemotherapy.5 The reduction of side effects was achieved by
replacing dichloride ligands with 1,1-cyclobutanedicarboxylate, which has a lower rate constant
of aquation, 10-8 s-1, compared with that of cisplatin (10-5 s-1).5, 11-12 After aquation, carboplatin
produces the same active species as cisplatin to form DNA adducts and is therefore effective in
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treating the same cancers as cisplatin, and the lower reactivity allows higher doses (300-450 mg
m-2) than cisplatin (20-120 mg m-2) in administration. The third platinum-based anticancer drug
succeeded in clinical trials and approved by FDA is another Pt(II) complex, oxaliplatin
([oxalate(2-)-O,O'][(1R,2R)-cyclohexanediamine-N,N’] platinum(II)) (Figure 1-1), under the
name of Eloxatin®. It was the first drug approved to be able to overcome cisplatin resistance and
also the first platinum-based drug that is active against metastatic colorectal cancer in
combination with fluorouracil and folinic acid.5, 13 In structure, two ammine ligands are replaced
by a single bidentate ligand (1R,2R)-cyclohexane-1,2-diamine (R, R-dach).14 This complex is
proposed to overcome cisplatin resistance by forming different adducts with DNA, that is, it
chiefly forms GpG intrastrand adducts. The bulky hydrophobic dach ligand points into the DNA
major groove therefore inhibits binding of DNA repair proteins.15
Since the discovery of cisplatin, although a large number of Pt(II) drugs which exhibit
anticancer activity have been discovered,16 only a few of them can be used in clinical therapy.17
Cisplatin, carboplatin and oxaliplatin are the only platinum-based drugs approved by FDA for
clinical use.18 Cisplatin and other Pt(II) complexes are vulnerable in the plasma as Pt(II) is easily
attacked by proteins containing thiol groups and this protein bonding reaction is blamed for
deactivation of cisplatin and some severe side effects.16 Moreover, cisplatin is also highly
cytotoxic toward rapidly dividing healthy cells hence its application is limited. As severe doselimiting side effects and acquired or intrinsic resistance to cisplatin are frequently observed,19,20 a
new generation of platinum drugs, Pt(IV) octahedral compounds, e.g. satraplatin (Figure 1-1), is
being developed to overcome these drawbacks. Platinum(IV) complexes, which have relatively
lower ligand exchange rates than Pt(II) are considered to be promising prodrugs of biologically
active Pt(II) complexes. Tobe and Khokhar and later Cleare et al.,21 suggested that Pt(IV)
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complexes may be reduced to Pt(II) complexes in vivo and later exert their cytotoxic effects in a
manner analogous to cisplatin and its analogs. The hypothesis was reinforced by the fact that in
clinical trials of a Pt(IV) complex, iproplatin, c,t,c-[PtCl2(OH)2((CH3)2CHNH2)2] (Figure 1-1),
cis-[PtCl2((CH3)2CHNH2)2] was detected in the plasma and urine, indicating that iproplatin was
reduced in the body to a Pt(II) complex.22-23 The octahedral structure of Pt(IV) allows more
modifications through introducing functional groups to axial positions without altering the
property of their active reducing product, because the Pt(IV) complexs will be metabolized and
lose the axial groups in blood. For instance, satraplatin (JM216), a Pt(IV) complex, is the first
orally bioavailable platinum compound investigated in active clinical trials. By introducing two
axial acetate groups, satraplain attains more lipophilicity, thus its oral bioavailability is
increased.
Ascorbic acid (AsA) and glutathione (GSH) are biological reducing agents frequently
cited in connection with the reduction of Pt(IV) complexes to Pt(II).24-26 Ascorbic acid, present in
blood plasma with a concentration of 50-150 M and the cytosol at ~1 mM,27-28 is a two electron
reducing agent capable of reducing Pt(IV) to Pt(II). The study of Blatter et al. 26 showed that the
AsA reduced species of iproplatin (Figure 1-1) and the related complex oxoplatin, c,t,c[PtCl2(OH)2(NH3)2], can bind to and unwind closed circular PM2 DNA. Green and Evans 29 and
Choi et al. 30 measured the second order rate constant for the ascorbate reduction of iproplatin at
40 oC obtaining k = 0.33 and 0.103 M-1 s-1, respectively, while Weaver and Bose25 investigated
the mechanism of reduction of oxoplain by ascorbate. The tripeptide, glutathione (GSH), glutamylcysteinylglycine, contains a cysteine thiol residue and is ~2 mM in the cytosol and ~850
M in blood.31-32 Reduced GSH is a potent one-electron reducing agent which is capable of
reducing Pt(IV) to Pt(II). However, the nature of the GSH-produced reduction products has been
5

the subject of inquiry. Recently, Volckova, et al.33 show that iproplatin is readily reduced by
GSH to produce cis-di(isopropylamine)chloro-glutathionatoplatinum(II) which has the thiolate of
a GSH molecule bound to Pt(II). Since this type of complex could not form a 1,2 intrastrand
crosslink with DNA,34 it was suggested that GSH-reduced iproplatin may exhibit its cytotoxic
effects by modifying biological targets other than DNA in the cell. Although the Pt(IV) complex
cis-[PtCl4(NH3)2] is considered a prodrug of cisplatin, Nakai, et al.35 have recently revealed that
the reduction by GSH of cis-[PtCl4(NH3)2] actually does not produce cisplatin. The study also
showed that in the presence of calf thymus DNA in the reduction medium, the Pt(II) product
produced which is captured by DNA does not form the 1, 2 intrastrand DNA crosslink. Gibson
and coworkers36-37 monitored the rate of reduction of Pt(IV) complexes in extracts obtained from
whole cells and they found that reductive elimination of cis-diam(m)inedichloridoplatinum(IV)
complexes with axial acetato ligands by whole cell extracts does exclusively produce a Pt(II)
product with the expected, cis-PtCl2N2 geometry. To investigate activation of Pt(IV) complexes,
Platts et al.38 monitored and correlated the electrochemical peak potentials and octanol-water
partition coefficients of 31 Pt(IV) complexes with the potential to produce cisplatin or cisplatintype complexes through reductive elimination to Pt(II) compounds. The study showed a good
correlation between the aforementioned properties and the calculated surface area, orbital
energies, dipole moments and atomic partial charges of the compounds and these investigators
developed models in the study which have the potential to predict the antiproliferative properties
of the compounds from calculated data.
Carbonate, in equilibrium with bicarbonate and dissolved CO2, is a crucial component of
the pH buffering system in human body and exists at high concentrations extensively in the
blood, interstitial fluid and cytosol. Van Eldik and coworkers revealed that metal hydroxo
6

species with cobalt, chromium, iridium, rhodium or zinc can react with dissolved CO2 and form
carbonato complexes with second order rate constants of k =37-590 M-1S-1 at 25 °C.39-41
Centerwall et al. revealed that cisplatin forms carbonato complexes cis-[PtCl(CO3)(NH3)2]- and
cis-[Pt(CO3)2(NH3)2]2- in carbonate buffer using HSQC NMR42 and research by Di Pasqua et al.
has shown that carboplatin can also form carbonato complexes.43 Later, Hong and coworkers
reported cisplatin-DNA monofunctional adducts are formed in the presence of carbonate and
carbonate prevents them from converting to bifunctional adducts.44 In this work, the influence of
carbonate in the binding of reduced species of oxoplatin and one of its Pt(IV) analogues c,t,c[PtCl2(OH)(O2CCH2CH2CO2H)(NH3)2], 3 (Figure 2-1), is studied to investigate the role of
carbonate in mechanism of action of platinum-based anticancer drugs.
To explore new possibilities of rapidly and selectively “arming” targeting vectors with
cytotoxic platinum complexes, we modified the prodrug of cisplatin, complex 3, by attaching 1adamantanemethylamine to the carboxylate functional group of the complex though EDC/NHS
crosslinking reaction to form the Pt-adamantane conjugate 4 (Figure 2-1). We also examined the
potential of host-guest interactions between -cyclodextrin and adamantane for delivery
applications involving the adamantane conjugate. Beta-cyclodextrin (CD), which is a cyclic
oligosaccharides composed of seven D(+)-glucopyranosyl units joined by α-1,4-glycosidic
bonds, is widely used as a host in pharmaceutical formulations for increasing the solubility,
stability and availability of drugs45-47 The hydrophilic outer surface of CD provides water
solubility through hydrogen bonds and the hydrophobic inner surface allows inclusion of small
molecules through a host-guest interaction driven by van der Waals forces. Adamantane (AD) is
a well-studied diamondoid hydrophobic guest molecule that binds to CD by rapid inclusion
with a binding constant, K ~ 102-103 M-1, 48-49 resulting in stable products. When this inclusion
7

complex is combined with a targeting vector equipped with CD, a conjugate having the
potential to direct platinum complexes to tumor sites is yielded. Halamikova et al. showed that
two adamantane-tethered platinum based complexes, t,t,t-[PtCl2(CH3CO2)2(NH3)(1adamantylamine)] and its reduced analog t-[PtCl2(NH3)(1-adamantylamine)] are able to
circumvent both acquired and intrinsic cisplatin resistance and have higher accumulation in
A2780 cells due to their lipophilic property.50 Earlier, Prashar et al. conjugated AD to an analog
of the Pt(II) anticancer drug carboplatin, and showed that the inclusion complex with CD is
more toxic toward human neuroblastoma SK-N-SH cells and delivers more platinum to closed
circular pBR322 DNA than carboplatin.51
In this study, to increase cancer targeting effect of the Pt(IV)-adamantane conjugate, a
cyclodextrin coated gold nanoparticle delivery system was constructed. Gold nanoparticles
(AuNPs), or gold colloids, were found to be used for therapeutic and decorative purposes in
ancient China and Egypt and was first reported by Faraday in scientific article in 1857.52-53 Gold
nanoparticles are synthesized conventionally by reduction of gold (III) derivatives. The simplest
and most prevalent method is reduction of HAuCl4 using trisodium citrate in aqueous solution,
firstly reported by Turkevitch in 1951,54 and refined by Frens in 1973 to obtain tunable size
between 16 and 147 nm by changing the ratio between the reducing agents to gold.55-56 In 2006,
Kimling et al. further modified the method and produced AuNPs with better controlled size
distribution within the range 9-120 nm.57 Citrate is a weak field ligand which stabilizes AuNPs in
aqueous solution; the AuNPs are usually subsequently functionalized using ligands of biological
interest by replacing citrate. A large variety of stabilizers such as ligands, surfactants, polymers,
dendrimers, biomolecules can be used to stabilize AuNPs, of which the most stable AuNPs
reported are capped with thiolates because of the soft acid-soft base interaction between gold
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and sulfur.58 Giersig and Mulvaney disclosed the synthesis of AuNPs stabilized by alkanethiols
of various chain lengths in 199359 while the most popular synthetic scheme of AuNPs is the
Brust-Schiffrin method published in 1994 using thiol as a stabilizer.60 Inspired by Faraday’s twophase system,52 Brust-Schiffrin biphasic synthesis is a convenient one-step method that
comprises growth of the metallic nuclei and simultaneous attachment of self-assembled thiol
monolayer on the nuclei, using HAuCl4, a thiol as a capping ligand, tetraoctylammonium
bromide as the phase-transfer reagent, NaBH4 as a reducing agent in water-toluene to produce
thiolate-AuNPs.
Gold nanoparticles are reported to have biocompatible properties such as nontoxicity,
nonimmunogenicity and high tissue permeability58, 61 and are widely investigated as drug
delivery vehicles to improve the biodistribution of drugs and achieve better targeting. Due to
their suitable size, nanoparticles are accumulated and entrapped in tumors through passive
targeting and will not be eliminated due to defense mechanisms of body therefore they keep
circulating in the blood stream and allow themselves to be taken to the target receptor. General
features of tumors include leaky blood vessels with gap sizes of 100 nm to 2 m and poor
lymphatic drainage which result in enhanced permeability and retention (EPR) effect of
AuNPs.62 Gold nanoparticles have become attractive drug delivery vehicles also because they
can be readily functionalized by ligands containing functional groups such as thiol, phospine,
phosphine oxide, amine and carboxylate, therefore allow delivery of various payloads to their
targets.53 In this work, AuNPs coated with per-6-thio-β-cyclodextrin, a hepta-thiol ligand, were
synthesized as a drug delivery vehicle for a Pt(IV) prodrug of the widely used anticancer drug
cisplatin. The cytotoxicity of the Pt(IV) complexed loaded AuNP delivery vehicle and the of the
system was tested toward human neuroblastoma (SK-N-SH).
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In vitro, cytotoxicity testing is widely used in basic research and clinical diagnostics.
These measurements of cellular sensitivity of cytotoxicity are dependent on a large number of
variables, one of which is recovery time that has been noted to be important but not well
explored. It is reported that when Murine leukemia L1210 cells is treated with cisplatin, low
concentrations of the drug causes the cells to be transiently arrested in the G2 phase for about 3
days before this phase is bypassed and growth is resumed.63 In another study, Bogdanovic et al.
reported that cisplatin analogs containing sulfur carrier ligands affected the growth of MCF7
human breast cancer cells during the recovery period and both inhibitory and stimulatory effects
on cell division were observed, depending on the platinum complex being investigated.64 This
makes the reported value of IC50 strongly dependent on the time (recovery period) at which
inhibition is measured. As the last part of this work, the dependence of IC50 of three metal
complexes on recovery time was investigated using human neuroblastoma cell line (SK-N-SH)
and ovarian cancer cell line (OVCAR-3).
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2. Pt (IV) Complexes as Prodrugs for Cisplatin

2.1 Introduction
It is widely accepted that Pt(IV) exhibit anticancer acitivity by being reduced to its Pt(II)
analogs in vivo 21 22-23 and ascorbic acid (AsA) and glutathione (GSH) are biological reducing
agents frequently cited in connection with the reduction of Pt(IV) complexes to Pt(II).

1
Cisplatin

2
Oxoplatin

3

Figure 2-1. Scheme for the synthesis of complexes 2 and 3.

In this chapter we first examined the ability of a Pt(IV) complex oxoplatin, 2, and one of
its carboxylate modified analogs, 3 (Figure 2-1), to produce cisplatin in the presence of the
biologically common reducing agents, ascorbic acid (AsA) and glutathione (GSH). Oxoplatin
exhibits potent oral anticancer activity 65-66 and its analogs has been used in a host of drug
delivery applications involving nanotechnology.67-69 The synthesis of oxoplatin was first reported
by Chugaev and Khlopin in 1927.70 Later studies of Presnov et al. showed that oxoplatin has a
wide spectrum of antineoplastic action therefore inhibits growth of solid and ascetic forms of
transplantable tumors.71 Olszewski et al. reported that oxoplatin induced S-phase arrest and cell
death in 38 cancer cell lines and the IC50 values are 2.5-fold higher that than its Pt(II) analog
11

cisplatin (1, Fig.1a)65. Since Pt(II) complexes bind to DNA, we used pBR322 DNA as a capture
agent for the reduction products of 2 and 3 and measured the mobility of the platinated DNA
forms in an agarose gel. It is known that physiological carbonate plays a significant role in the
speciation of cisplatin in solution and thus affects the kinetics of the platinum-DNA interaction
and possibly the type of the DNA adduct formed.42-43, 72-77 Therefore, we also investigated
platinum binding to pBR322 DNA in the presence and absence of carbonate buffer. We used
195

Pt NMR to identify the nature of the platinum species formed in the reduction and 13C NMR to

detect Pt(II) carbonato complexes when the reduction is carried out in carbonate media.
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2.2 Materials and Methods
2.2.1 Instrumentation
One dimensional 1H NMR spectra were obtained using a Bruker Avance 300 MHz
spectrometer with chemical shifts determined by setting the hydrogen impurity in DMSO-d6 to
2.50 ppm. One dimensional 195Pt NMR spectra were recorded on a Bruker Avance 500 MHz
NMR instrument utilizing either a Nalorac 5 mm indirect detection gradient probe or a Nalorac
10 mm broadband observe probe. A solution of 10 mM potassium hexachloroplatinate in 95%
H2O/5% D2O was used as an external standard (0 ppm). All experiments were done at 25 oC
using a 2 s relaxation delay time and a spectral width of 600 ppm with 32K points. One
dimensional carbon-13 NMR spectra were recorded at 25 oC on a Bruker Avance 500 MHz
NMR instrument equipped with a 5 mm Bruker QXI gradient probe. The standard 13C pulse
sequence was used with proton broad-band decoupling and a spectral window of 250 ppm. The
relaxation delay was set to 2 s, the total number of points to 16K, and the total number of scans
set to 6000. The internal chemical shift standard, set at 126.1 ppm, was 13CO2(aq). Infrared
spectra were obtained on nujol mulls using a Nicolet 200 FT-IR spectrometer and the mass
spectral data were obtained using positive electrospray ionization with a Bruker 12 Tesla APEXQe FTICR-MS with an Apollo II ion source (COSMIC Lab, Norfolk, VA).

2.2.2 Synthesis of Oxoplatin (2)

This compound was synthesized in a manner analogous to that earlier reported by
Brandon and Dabrowiak.76 Hydrogen peroxide (30 wt %, 20 mL) was added dropwise to a

13

suspension of cisplatin, 1, (0.4 g, 1.33 mmol) in H2O (12 mL) at 65 °C. After 4 h, the bright
yellow solution was cooled at room temperature overnight to afford yellow crystals. The crystals
were recovered by filtration, washed with ice cold water and dried in vacuo. Yield: 65.6% (0.291
g, 0.872 mmol). IR 3458 (s, OH stretch), 1072 (m, Pt-OH bend), 536 (m, Pt-N(O) stretch). 195Pt
NMR (500 MHz, D2O), δ (ppm) = 853.

2.2.3 Synthesis of c,t,c-[PtCl2(OH)(O2CCH2CH2CO2H)(NH3)2] (3)
This compound was synthesized in a manner analogous to that described by Dhar et al.68
To a suspension of compound 2 (0.2 g, 0.6 mmol) in DMSO (16 mL) was added succinic
anhydride (0.06 g, 0.6 mmol) and the mixture was stirred overnight at RT to afford a bright
yellow solution. After reducing the volume of the solution in vacuo to ~ 0.5 mL, addition of ~10
mL of ice cold acetone caused precipitation of a pale yellow solid, which was collected via
filtration, washed with acetone and dried in vacuo. Yield: 97.2% (0.253g, 0.583 mmol). 1H NMR
(300 MHz, DMSO-d6), δ (ppm) = 5.93 m, 6H (NH3); 2.39 m, 4H (CH2). J(1H-195Pt) = 103.2 Hz,
J(1H-14N) = 25.5 Hz. 13C NMR (75 MHz, DMSO-d6): δ = 179.73 (C=O), 174.19 (C=O), 30.21
(CH2), 31.24(CH2) ppm. MS (1:1 THF:MeOH with NaCl) calculated m/e of
(C4H12N2O5Cl2Pt)Na+ = 456.0, observed m/e = 456.0. 195Pt NMR, δ (ppm) = 944.

2.2.4 DNA Binding Studies of Pt(IV) Complexes to pBR322 DNA
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The DNA binding/capture studies were done in a total volume of 20 μl containing 38.5
μM (bp) pBR322 DNA (New England BioLabs Inc.), in 12 mM HEPES, N-(2hydroxyethyl)-piperazine-N'-2-ethanesulfonicacid (pH 7.4) buffer or, when sodium bicarbonate
was present, in 12 mM HEPES buffer plus 12 mM sodium bicarbonate (pH 7.4). The two
reducing agents used were glutathione (GSH, 2 mM) and ascorbic acid (AsA, 50 μM). Cisplatin,
1, was used as purchased (Sigma-Aldrich, St. Louis, MO). Stock solutions of the platinum
compounds in distilled water, 1 and 3, or DPBS (Dulbecco’s phosphate buffered saline) buffer,
4, were in the range of 40–650 μM. Appropriate volumes of the stock solutions were added to
solutions containing the buffer and DNA to give the final concentrations given above and values
of r, where r = [platinum compound]/[DNA-bp], given in the captions to figures. The samples
were incubated at 37 °C for 24 h in sealed Eppendorf tubes after which time 2.5 μl of a loading
dye containing 50% glycerol, 0.25% bromophenol blue and 0.25% xylene cyanol was added. An
8 μl volume of each sample containing the loading dye was loaded in the wells of a 1% agarose
gel. Electrophoresis was carried out for a period of ~4 h, at 100 V. After electrophoresis, the gel
was immersed in 300 ml of deionized water containing 300 μl of a 0.5 mg/ml solution of
ethidium bromide for 30 min to stain DNA, and then soaked in water alone for 15 min to de-stain
the background of the gel. A digital image of the stained gel was captured using a Kodak Gel
Logic 100 imaging system equipped with Fisher Biotech IT-88A transilluminator. This DNA
binding study was performed by Shu-An Liu (University of Technology Graz) under this
author’s direction.

2.2.5 195Pt NMR of Pt(IV) Complexes in the Presence of Ascorbic Acid or Glutathione in
pH 7.4 Buffer with or without NaHCO3
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Compound 3 (10 mM) was incubated at 37 oC for 24 h in the presence of 10 mM ascorbic
acid or 20 mM GSH in 12 mM HEPES buffer with or without 12 mM NaHCO3, pH 7.4.
Compound 4 (10 mM) was incubated at 37 oC for 24 h in the presence of 10 mM ascorbic acid or
20 mM GSH in DPBS buffer with or without 12 mM NaHCO3, pH 7.4. The solvent of the above
samples was H2O/D2O (95/5) and the concentrations given are the final concentrations.

2.2.6 13C NMR of Pt(IV) Complexes in the Presence of Ascorbic Acid in pH 7.4 Buffer with
NaH13CO3
Compound 3 (10 mM) was incubated at 37 oC for 24 h in the presence of 10 mM ascorbic
acid in 12 mM HEPES buffer with 0.5 M NaH13CO3, pH 7.4. Compound 4 (10 mM) was
incubated at 37 oC for 24 h in the presence of 10 mM ascorbic acid in DPBS buffer with 0.5 mM
NaH13CO3, pH 7.4. The solvent of the above samples was H2O/D2O (90/10); the final
concentrations in the reaction mixture are given.
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2.3. Results

2.3.1 DNA Capture-Gel Electrophoresis Experiments

(a)

(b)

(c)
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(d)

(e)

(f)
Figure 2-2. (a)-(f) Ethidium bromide stained agarose gels of pBR322 DNA (38.5 M). (a)-(e),
pBR322 DNA in the presence of either 2, or 3, in the absence or presence of 12 mM sodium
bicarbonate with either ascorbic acid, AsA (50 μM) or glutathione, GSH (2 mM) as the reducing
agent. The fastest migrating band (bottom band) is covalently closed circular form I DNA while
the slowest migrating band (top band) is nicked circular form II DNA. (a) Compound 2, AsA,
sodium bicarbonate, lanes 5-11; no bicarbonate, lanes 12-18. For this and the subsequent gels,
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lane, r, i.e., the lane number followed by r where, r = [compound]/[DNA-bp], are given. Lane, r:
5, 0.26; 6, 0.52; 7, 1.04; 8, 1.17; 9, 1.30; 10, 1.43; 11, 1.56; 1, 0 (DNA); 2, 0 (DNA + AsA); 3, 0
(DNA + bicarbonate); 4, 0 (DNA + AsA + bicarbonate). The values of r for lanes 12-18 are the
same as for lanes 5-11. (b) Compound 3, AsA, sodium bicarbonate, lanes 5-11; no bicarbonate,
lanes 12-18. Lane, r: 5, 0.26; 6, 0.52; 7, 1.04; 8, 1.17; 9, 1.30; 10, 1.43; 11, 1.56; 1, 0 (DNA); 2,
0 (DNA + ascorbic acid); 3, 0 (DNA + bicarbonate); 4, 0 (DNA + ascorbic acid + bicarbonate).
The values of r for lanes 12-18 are the same as for lanes 5-11. (c) Compound 2, GSH, sodium
bicarbonate, lanes 5-11; no bicarbonate, lanes 12-18. Lane, r: 5, 1.69; 6, 3.38; 7, 5.06; 8, 6.75; 9,
7.60; 10, 8.44; 11, 10.13; 1, 0 (DNA); 2, 0 (DNA + GHS); 3, 0 (DNA + bicarbonate); 4, 0 (DNA
+ GSH + bicarbonate). The values of r for lanes 12-18 are the same as for lanes 5-11. (d).
Compound 3, GSH, sodium bicarbonate, lanes 5-9; no bicarbonate, lanes 12-18. Lane, r: 5, 1.30;
6, 2.60; 7, 3.90; 8, 5.19; 9, 5.84; 10, 6.49; 11, 7.79; 1, 0 (DNA); 2, 0 (DNA + GSH); 3, 0 (DNA
+ bicarbonate); 4, 0 (DNA + GSH + bicarbonate). The values of r for lanes 12-18 are the same as
for lanes 5-11. (e). Compound 3, GSH. Lane, r: 3, 1.30; 4, 1.49; 5, 1.69; 6, 1.88; 7, 2.08; 8, 2.27;
9, 2.60; 10, 2.92; 11, 3.25; 12, 3.57; 13, 3.90; 14, 4.22; 15, 4.55; 16, 4.87; 17, 5.19; 18, 5.52; 1, 0
(DNA); 2, 0 (DNA + GSH). (f) Compound 1, cisplatin, 2 mM GSH in 12 mM HEPES buffer, pH
7.4, lanes 3-9; no GSH, lanes 11-17, the values of r for lanes 3-9 and 11-17 are the same
(condition error, lane 13). Lane, r: 3 (11), 0.08; 4 (12), 0.09; 5 (13), 0.10; 6 (14), 0.11; 7 (15),
0.12; 8 (16), 0.13; 9 (17), 0.14; 1 (10), 0 (DNA), 2, 0 (DNA + GSH).
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(a)

(c)

(b)

(d)

(e)
(f)
Figure 2-3. Distance of migration of the band from the loading well in the gel in arbitray units as
a function of r, where r = [Pt]/[DNA-bp], referred to as mobility plots, for the agarose gels
shown in Figure 2. The lines shown are linear fits to the data. Square is closed circular Form I
pBR322 DNA in the presence of carbonate; triangle is Form I DNA without carbonate; circle is
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nicked circular Form II DNA in the presence of carbonate; diamond is Form II DNA in the
absense of carbonate.

Figure 2-2(a)-(e) show images of agarose gels of pBR322 DNA in the presence of
reducing agents and either 2 or 3 in aqueous solutions with or without carbonate while Figure 22(f) shows the binding of cisplatin, 1 to pBR322 DNA in the presence and absence of GSH. In
Figure 2-2(a)-(f), the distance of migration of the DNA form from the loading well in arbitrary
units is plotted versus r, where r = [Pt]/[DNA-bp], with linear fits to the data. As the initial
concentrations of DNA, the reducing agent, carbonate (when present) and time are kept constant
in the experiments, the plots show changes in DNA mobility as a function of the total initial
concentration of Pt(IV) complex. In these experiments pBR322 DNA which has both closed and
nicked circular forms, was used as capture agent for the reduction products, Pt(II) compounds,
which bind to the DNA forms therefore affect mobilities of DNA in the gel. Since
electrophoresis conditions varied slightly from experiment to experiment, and these affect the
distance of migration in the gel, the slope from the linear fits to the data in Figure 2-3 were
divided by the y-intercept to give relative slopes, which are presented in Table 1 with statistical
errors.
The agarose gel image of pBR322 DNA with oxoplatin, 2 in the presence of reducing
agent ascorbic acid (AsA) is shown in Figure 2-2 (a) and Figure 2-3(a) and the mobility plots and
their relative slopes given in Table 2-1. Two bands of major forms of pBR322 Form I (closed
circular), the fast migrating form and Form II (nicked circular), the slow migrating form, are
shown in each lane. When carbonate is present, the relative slopes of Form I and II are close to
zero which means that mobility is neither changed nor dependent on r, suggesting that the Pt(II)
species produced in the reduction are not binding to DNA. When carbonate is absent from the
21

Systema
AsA and 2 (a)
AsA and 3 (b)
GSH and 2 (c)
GSH and 3 (d)
GSH and 3 (e)

cisplatin (f)

Form Ib
no data
13.2 ± 7.5 (+)
±
18.0 ± 3.5 (+)
15.5 ± 2.4c (+)

(1.92 ± 0.96)103 (+)

Form II
45 ± 15 (+)
6.1 ± 12.4 (0)
6.2 ± 0.6 (+)
±
±c

Form I + HCO3
7.8 ± 5.2 (0)
±0
0.9 ± 1.2 (0)
1.6 ± 0.7 (+)
no data

Form II + HCO3
3.6 ± 4.4 (0)
11.4 ± 7.3 (+)
3.0 ± 1.5 (+)
1.9 ± 0.5 (+)
no data

260 ± 110 (

Form I + GSH
± 340 (

Form II + GSH
630 ± 100 (+)

a

Refers to the reducing agent and the Pt(IV) compound involved in the reduction reaction; the
letter in parenthesis refers to the gel image in Figure 2 and the mobility plot in Figure 3. The
values given in the table are relative slopes of the linear fits to the mobility plots shown in Figure
3 in units of r-1 multiplied by 103, followed by the sign of the slope in parentheses, r =
[Pt]/[DNA-bp]. Positive and negative slopes indicate that the DNA form migrates faster and
slower, respectively, with increasing r, than the same form in the absence of added platinum
compound. bForm I and Form II are closed and nicked circular pBR322 DNA, respectively.
c
For (e), a much better fit (sum of square deviations = 60 instead of 377) is obtained by using one
line for r < 3.3 and a second for r > 3.3).
Table 2-1. Relative slopes (slope divided by the y-intercept) from the mobility plots shown in
Figure 2-3, with statistical errors.

medium Form I is hard to observe while Form II runs slightly faster than its counterpart without
carbonate and its mobility plot has a positive relative slope (the mobility of DNA increases with
r), Table 1. The difficulty in detecting Form I (only a weak band for this form is observed in lane
12) suggests that Form I is co-migrating with Form II at some values of r and/or the crosslink
blocks ethidium bromide binding to DNA leading to reduced staining.73 The increase in mobility
and positive slope of Form II is consistent with the formation of the well-known cisplatin 1, 2
intrastrand crosslink. 195Pt NMR shows that the reduction of 2 by AsA produces cisplatin and its
aquated/substituted products and 13C NMR indicates that in carbonate media Pt(II) carbonato
complexes have formed.
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Figures 2-2(b), 2-3(b) and Table 1 show the results of the DNA capture experiment when
the oxoplatin analog, 3, is reduced by AsA in the presence and absence of carbonate. In the
presence of carbonate, mobilities are like those of the controls with the slope of Form I zero and
the slope of Form II small and positive with a substantial uncertainty indicating no DNA binding
formed. In the absence of carbonate, Figure 2-2(b) and 2-3(b) show that the mobilities of both
DNA forms are evidently different than the controls indicating that binding of Pt(II) to has
occurred. As shown in Table 2-1, the slope for Form II is zero while the slope for Form I is likely
positive. Dulbecco's phosphate-buffered saline (DPBS), which contains chloride ion, is used as
the stock solution of 3. Since the chloride ion suppressed the aquation of cisplatin, the crosslink
appears to be formed but shows not much change in the mobility of Form I with r.

195

Pt NMR

shows that the reduction of 3 with AsA produces cisplatin without its aquated/substituted
products and 13C NMR indicates that in carbonate media Pt(II) carbonato complexes are formed.
Figures 2-2(c), 2-3(c) and Table 2-1 give the results of the DNA capture experiment
when 2 is reduced by GSH. In the presence of carbonate, the mobilities of both forms are similar
to controls with the relative slope of Form I zero and the slope of Form II slightly positive with a
significant error showing that carbonate efficiently blocks the binding of Pt(II) products to DNA.
However, in the absence of carbonate, the mobility of Form I is decreased comparing to the
control and its relative slope is negative (mobility decreases with r) while the slope of Form II is
positive (mobility increases with r). 195Pt NMR analysis shows that reduction of 3 with GSH
does not produce cisplatin.
Figures 2-2(d) and 2-3(d) show the effects on pBR322 DNA mobility when oxoplatin
analog, 3, is reduced by GSH. When carbonate is present, the mobilities of both forms are similar
to those of the controls as predicted and the slopes of both forms are only slightly positive
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showing little platinum binding to DNA, Table 1. When carbonate is absent, the mobilities of
both forms decrease compared to controls and the relative slopes of both forms are significant
with Form I having a positive slope (mobility increases with r) and Form II a negative slope, and
the results are opposite to what is observed for 2 being reduced by GSH Figures 2-2(c) and 23(c), Table 2-1.
To further explore the DNA capture experiment involving the reduction of 3 by GSH in
the absence of carbonate, a larger number of values of r in the range of 1.3-5.52 with smaller
intervals were investigated, (Figures 2-2(e) and 2-3(e) and Table 2-1). It is evident that both
forms are shifted from the controls and their mobilities change systematically with r. From linear
fits of the mobilities to r, Form I has a positive slope while Form II a negative slope with signs
and magnitudes comparable to those observed in Figures 2-2 (d) and 2-3 (d) and Table 2-1.
However closer inspection reveals that the mobility is weakly bimodal in nature with much better
fits to the data being obtained by two lines, one for r < 3.3 and a second for r > 3.3 (see Table 21). While the mobility of Form I is closer to that of Form II for higher r, the two forms never comigrate. 195Pt NMR analysis shows that reduction of 3 with GSH does not produce cisplatin.
Figures 2-2(f) and 2-3(f) show cisplatin binding to pBR322 DNA in the presence and
absence of GSH with the relative slopes of the mobility plots given in Table 2-1. In the presence
of GSH Forms I and II have large negative and positive slopes, respectively which is the same
slope pattern observed for the reduction of 2 with GSH in the absence of carbonate. This suggest
that some cisplatin may also be produced in the reduction of 2 by GSH and that possibly a
cisplatin-GSH complex is interacting with DNA. In the absence of GSH, the mobility of Form I
is much lower than the control and Forms I and II nearly co-migrate at r = 0.9. In Table 1, the
magnitudes of the relative slopes of both forms are much larger than any other slope revealing
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that the effect of the drug on the mobility of the form is significant due to the formation of the 1,
2 intrastrand crosslink. Since the slope of Form I is positive, the writhe is positive indicating a
high loading of platinum on DNA.77-78 The negative slope for Form II is also consistent with a
high loading of platinum on DNA.
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2.3.2 195Pt NMR

Figure 2-4. 195Pt NMR spectra. (a) Reduction of oxoplatin, 2, with AsA. (b) Reduction of
oxoplatin, 2, with GSH. (c) Reduction of the oxoplatin analog, 3, with AsA. (d) Reduction of
the oxoplatin analog, 3, with GSH.
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195

Pt NMR was used to identify the nature of the platinum species in solution when 2 and

3 are reduced by either AsA or GSH. The incubation time of the reduction solution was 24 h,
after which time NMR spectra were obtained; the solutions contained no DNA. Also, the ratio of
reducing agent to platinum complex was 1:1 for AsA reducing 2 and 3 and 2:1 for GSH reducing
2 and 3, much different than the ratios employed in the DNA capture-gel studies. The choice of
ratios of reducing agent to platinum was largely influenced by the relatively low sensitivity of
195

Pt NMR which required millimolar concentrations of the platinum complex in the NMR tube.

The concentration of the reducing agent, if the ratios used in the gel studies were to be
maintained, would be unrealistically large. In these reactions, ascorbic acid acts as a two electron
reducing agent to convert one molecule of a Pt(IV) complex to a Pt(II) product and the AsA is
oxidized to dehydroascorbic acid.25 In the case of the reduction of the Pt(IV) complex with
iproplatin, three molecules of GSH are required to completely reduce one molecule of 2. Two
GSH molecules supply the two electrons necessary to convert Pt(IV) to Pt(II) (producing the
disulfide, GSSG), and one molecule of GSH, in its deprotonated form, becomes bound to Pt(II)
to give as the final product, cis-di(isopropylamine)chloro-glutathionatoplatinum(II), cis[PtCl(GS)(NH2CH(CH3)2)2].33
The 195Pt NMR spectra of the platinum species observed in the reduction reactions are
shown in Figure 2-4. Figure 2-4(a) shows that the reaction of 2 with AsA in 12 mM HEPES
buffer produces a strong signal for cisplatin at -2140 ppm, a number of weak signals in the
region -1670 to -1830 ppm for Pt(II) species having a PtN2O2 coordination environment,79 and a
weak signal for unreacted 2, at 853 ppm. Interestingly, when two equivalents of GSH are used as
the reducing agent for oxoplatin, only a signal of reduced intensity for 3 is observed in the 195Pt
NMR spectrum at 853 ppm, i.e., no Pt(II) products are observed, Figure 2-4(d). Although an
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exhaustive search in the chemical shift range -4000 to 1500 ppm failed to find additional 195Pt
NMR resonances, the electrophoresis results clearly show that some Pt(II) complexes are
produced in the reduction and that they bind to DNA, Figures 2-2(c), 2-3(c) and Table 2-1.
Figure 2-4(c) shows the 195Pt spectrum of the oxoplatin analog, 3, 24 h after exposure to
one equivalent of AsA in DPBS buffer. As is evident from the figure, the only detectable 195Pt
NMR signal is the strong peak at -2140 ppm which is due to cisplatin. The absence of the Pt(IV)
starting material at 943 ppm shows that the reaction of 3 with AsA went to completion. In
addition, the lack of Pt(II) aqua species and/or cisplatin reaction products with ascorbate or
dehydroascorbic acid, as in Figure 2-4(a), shows that the presence of a high concentration of
chloride ion, ~140 mM, in DPBS, suppresses the reaction of cisplatin with components in
solution keeping the drug in its dichloro form.
The 195Pt NMR spectrum of the reaction of 3 with two equivalents of GSH for 24 h in
DPBS buffer only exhibits a resonance (of reduced intensity) for the unreacted complex, 3, at
943 ppm, i.e. no resonances for cisplatin/other Pt(II) complexes are observed, Figure 2-4(d).
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2.3.3 13C NMR

Figure 2-5. 13C NMR spectra of the products of reduction of 2 (top spectrum) and 3 (bottom
spectrum) with ascorbic acid in the presence of NaH13CO3
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In addition to 195Pt NMR, the reduction of 2 and 3 with AsA, which produces cisplatin,
was monitored with 13C NMR in the presence of H13CO3-. Figure 2-5 shows that the reduction of
either compound with AsA produces a number of Pt(II) carbonato complexes which have
resonances on the low field side of free bicarbonate ion at 162.0 ppm.42-43 Reduction of 2 in
carbonate produces carbonato resonances at, 168.1 – 168.7 ppm, while reduction of 3 with AsA
gives a group of carbonato resonances in the region 167.2 – 169.7 ppm. Since carbonato
complexes reduce the binding of cisplatin to DNA,73-75 the 13C NMR results explain the observed
decrease in binding of Pt(II) compound to DNA when carbonate is present in the reduction
medium, Figures 2-2, 2-3 and Table 2-1.
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2.4. Discussion
The study of Bose and coworkers 25 include the kinetics and mechanism of reduction of
oxoplatin, 2, with AsA and iproplatin, with GSH, showing that AsA reduces 2 with a second
order rate constant of ~2 M-1s-1 at pH 7.3 at 22 oC and that cisplatin is produced by the reduction.
As shown in Figure 2-5, in this work cisplatin is produced in the reduction and 195Pt NMR
spectra (Figure 2-4) further indicate that the drug reacts during the 24 h reaction period to
produce Pt(II)N2O2 type products. These products appear to be aquated and/or carboxyl
substituted products of the drug, the carboxylate ligand most likely being supplied by
dehydroascorbic acid.79 Although the reduction reaction of 2 by AsA would be expected to have
an approximate half-life of ~ 1 min under the conditions of the 195Pt NMR experiment ([AsA],
[3] =10 mM, 37 oC), interestingly, not all 2 has been reduced to Pt(II) products as revealed by the
remaining relatively weak resonance at 853 ppm (Figure 2-5). One possible cause is the
stoichiometry of the reduction is not 1:1. Since aquated and/or carboxyl substituted products of
cisplatin should react with DNA to form the 1, 2 intrastrand crosslink, the 195Pt NMR results
corroborated the analyses of the gel DNA mobility studies which suggest that the reduction
product of 2 with AsA produces the crosslink, Figures 2-3(a), 2-4(a) and Table 2-1.
In Figure 2-4 (b), it shows that when oxoplatin is reduced by GSH at a 1:2 ratio of
reactants, only a weakened signal for 2 at 853 ppm is observed in the 195Pt NMR spectrum.
Although it is evident that a reaction has taken place, no Pt(II) products have been detected by
the 195Pt NMR spectrum. In the case of the related complex, iproplatin, reduction with GSH
occurs with a second order rate constant of 0.49 M-1s-1 at 22 oC at pH 7.0 with three molecules of
GSH being required to reduce one equivalent of iproplatin to produce, cisdi(isopropylamine)chloro-glutathionatoplatinum(II).33 Since iproplatin and oxoplatin have
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similar structures, it is reasonable to assume that 2 would also react with GSH in a 1:3
stoichiometry which explains the peak at 853 ppm as due to remaining 3 in the 195Pt NMR
sample. Moreover, if the rates of reaction for iproplatin and 2 with GSH are similar, the t1/2 of the
reaction of 2 with GSH under the conditions of 195Pt NMR experiment ([GSH], [2] =10 mM, 37
o

C) is ~3 h, so that the reaction is complete after 24 h incubation. Volckova et al. 33 show that

reduction of iproplatin with GSH produces cis-di(isopropylamine)chloroglutathionatoplatinum(II), the corresponding Pt(II) complex for the reduction of iproplatin, but
cis-diamminechloro-glutathionatoplatinum(II), cis-[PtCl(GS)(NH3)2], is not detected in Figure 24(b) in which resonance would be expected at ~-3000 ppm.79 Failure to observe the Pt(II)
product (s) in the 195Pt NMR spectrum highly suggests that although the Pt(II)-GSH adduct is
formed, due to the polydentate nature of GSH and the long reaction period, 24 h, it converts to
other species, each of which has too low intensity to be detected in the NMR experiment. The
DNA capture experiments evidently show that a Pt(II) complex has been produced in the
reaction, and is captured by DNA. However, its effect on the supercoiling of DNA is different
from that of cisplatin, i.e., the 1, 2 intrastrand crosslink is not formed, Figures 2-2(f) and 2-3(f),
Table 2-1.31, 73-75If the initial reduction product in the reaction is cis-[PtCl(GS)(NH3)2], it could
react with DNA through the loss of the chloride ligand to produce a monofunctional adduct, but
due to the presence of the thiolate ligand, the monofuctional adduct would not be likely to
produce an intrastrand crosslink.
The reduction of 3 by AsA is similar to that of oxoplatin except that only cisplatin is
observed in the 195Pt NMR spectrum, Figure 2-4(c), indicating that the reaction is complete. The
absence of hydrolysis products and/or reaction products of cisplatin is explained by the high
chloride concentration in the DPBS buffer (~140 mM) in the 195Pt NMR sample. Since the
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reduction of 3 with AsA in the presence of DNA (no carbonate) was carried out in DPBS buffer,
some reactive Pt(II) species should be present which explains the mobility difference of Form I
DNA relative from its control, Figures 2-2(b) and 2-3(b). However, in this case mobilities are
essentially independent of r. This is because [Cl-] is relatively high and, as chloride suppresses
DNA binding, mobilities are not very sensitive to r, Table 2-1.
The 195Pt NMR spectrum of the reduction of 3 with GSH is similar to that of 2 with GSH
in that only some of unreacted Pt(IV) complex remains after 24 h in the NMR solution. While
this agrees with the reaction stoichiometry of iproplatin with GSH, Volckova et al. 33, i.e., some
Pt(IV) should remain unreacted, Pt(II) products are not detected in the NMR spectrum. However,
in the DNA gel study of this reduction in the absence of carbonate, DNA captures a Pt(II)
complex. The bound platinum does not affect mobility in the same way as the intrastrand
crosslink which means Forms I and II never co-migrate at any value of r, Figures 2-2(d,e) and 23(d,e), Table 1. Comparing to the reaction of 2 reduced by GSH, the Pt(II) product is likely cis[PtCl(GS)(NH3)2] which would be expected to bind to DNA in a mono-functional manner (loss
of Cl-) and not produce the intrastrand crosslink.
Figure 2-5 shows 13C NMR spectra of reductions of 2 and 3 with AsA in the presence of
13

C-labeled carbonate. As is observed from the spectra, 13C NMR resonances in the region 167.2

– 169.7 ppm indicate the formation of Pt(II) carbonato complexes. It is well known that
carbonato complexes can form by two paths: the first is a conventional ligand substitution
reaction at the metal center, in which carbonate is exchanged with a ligand bound to the metal
ion; the second is by a unique and rapid route in which the oxygen atom of a metal-bound
hydroxo ligand attacks the carbon atom of molecular carbon dioxide, to produce a bound
carbonate (hydrogencarbonate) ligand, Figure 2-6.80 As the latter reaction does not involve a

33

metal-ligand bond breaking step, this reaction rate is much higher than conventional ligand
exchange reactions, which is are in the range of 50-600 M-1 s-1 depending on the metal ion.80 The
13

C NMR spectra (Figure 2-6) show that there are a larger number of distinct carbonato species

formed in the reduction of 3 with AsA than that of 2. The additional carbonato species observed
could be due to the liberated dicarboxylate ligand which could act as a ligand toward Pt(II) and
therefore increase the number of carbonato products detected in the reaction.
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Figure 2-6. Scheme showing the reaction of a Pt(II) aqua species with molecular carbon dioxide
and associated equilibria.

After the initial report of the anticancer activity of cisplatin, Rosenberg proposed that the
anticancer properties of the drug are due to its ability to form an intrastrand crosslink at two
adjacent purine bases of DNA.81 Subsequent work by many research groups confirmed the
existence of this type of lesion, finding that an adduct at the sequence GG is most common.31
The mechanism for cisplatin binding to DNA starts with the formation of a mono-aqua complex
with positive charge, cis-[PtCl(H2O)(NH3)2]+, which further reacts with N-7 of guanine through
the loss of a water molecule to form the monofunctional adduct cis-[PtCl(G)(NH3)2]+.82 This
DNA adduct then converts to the 1, 2 intrastrand crosslink, cis-[Pt(GG)(NH3)2]+2, directly
through the loss of the chloride ligand from Pt(II) or through an intermediate step also involving
the aqua complex. When carbonate is present, the bound water molecule of cis-
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[PtCl(H2O)(NH3)2]+ may be partially or fully converted into a carbonate form, as shown in
Figure 2-6. Moreover, as carbonate/hydrogencarbonate is a poorer leaving ligand than water,83
binding of the complex to DNA would be reduced which is corroborated by the gel studies that
show that binding is insignificant in the presence of carbonate.73-75
Todd et al. 75 argued that carbonate in the medium does not change the type of adduct
formed on DNA, i.e. the 1, 2 intrastrand crosslink is still formed under this condition, with
reduced amount of the crosslink that forms. However, characterization of the DNA adduct in
these studies required techniques (HPLC, mass spectrometry, etc.) that would allow CO2 gas to
escape from the system. This could shift the equilibria given in Figure 2-6 to the left and, the
cisplatin-DNA adduct that initially forms in carbonate could have been destroyed without being
noticed in the workup thus producing and leaving only the 1, 2 intrastrand crosslink. Binter et al.
73

on the other hand measured mobilities and band intensities of platinated DNA in gel

electrophoresis experiments revealing that the presence of carbonate causes cisplatin to form a
monofunctional adduct on DNA. While these studies had none of the structural characterization
rigor of the study by Todd et al.,75 they were much less prone to shifts in the chemical
equilibrium in Fig.2-6. In a later study, Sorokanich et al.74 were unable to reproduce the band
intensity changes observed by Binter et al.73 but the investigators found that at large values of r,
Forms I and II never co-migrate in the gel. This again suggested that the adduct in the presence
of carbonate is different from the 1, 2 intrastrand crosslink. The living cell maintains a cytosolic
concentration of ~12 mM carbonate, of which dissolved CO2 is an important component.
Therefore cisplatin adducts that form on genomic DNA are exposed to a “carbonate pressure”
that may be difficult to imitate in laboratory experiments. Since carbonate can change the
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speciation of cisplatin and carboplatin, additional study on how carbonate influences the rate and
mechanism of the formation as well as the structure of the DNA adduct is meaningful.
Using the published rate constants for the reduction of 2 with ascorbic acid and reduction
of iproplatin with GSH,25, 33 it is interesting to speculate on the Pt(II) products formed if 2 and 3
are present in blood. While kAsA/kGSH ~ 4, the ratio [AsA]/[GSH] in blood (plasma) is 100
mM/850 mM = ~ 0.12 27-28, 31-32 suggesting that only half (4 x 0.12) of the reduction product
would be cisplatin, reduction product by AsA, with the remaining half being a non-cisplatin
complex, formed by GSH reduction. Another aspect is that the reduction potentials of 2 and 3 are
0.82 and 0.46 V (NHE),68, 84 respectively. This shows that 3 is more easily reduced than 2.
The reduction potentials for AsA and GSH are 0.065V and 0.16V respectively, so that GSH is
a slightly stronger reducing agent than AsA.85-86 Since the circulation time of a particle in the
blood is 1-10 h, there would be enough opportunity for a compound such as 3 to be reduced on
the way to the tumor site.25, 33-35 The platinum “cargo” released from the carrier before the
vehicle reaches its intended target could also reach and kill tumor cells, which could impart
characteristics to the delivery system that are a combination of both the nano-carrier and the free
drug.
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2.5. Conclusions
In this work we show that oxoplatin, 2, and its analog, 3, can be reduced to by the
biologically common reducing agents ascorbic acid and glutathione. The reduction product by
AsA is cisplatin while treatment of the Pt(IV) compounds with GSH does not produce cisplatin.
The gel analyses show that the Pt(II) product(s) produced by GSH bind to closed circular
pBR322 DNA without formation of the well-known 1, 2 intrastrand DNA crosslink which is
characteristic of cisplatin binding to DNA. It is also shown that in the presence of physiological
carbonate, Pt(II) products from reduction of 2 and 3 are prevented from binding to pBR322
DNA.
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3. Functionalized Gold Nanoparticle as a Delivery Vehiclefor a Prodrug of Cisplatin
3.1 Introduction
Gold nanoparticles are reported to have biocompatible properties such as nontoxicity,
nonimmunogenicity and high tissue permeability and are widely investigated as drug delivery
vehicles to improve the biodistribution of drugs and achieve better targeting.58, 61 In this work,
AuNPs (5, Figure 3-1) coated with per-6-thio-β-cyclodextrin (7, Figure 3-1), a hepta-thiol ligand,
were synthesized as a drug delivery vehicle for a Pt(IV) prodrug of the widely used anticancer
drug cisplatin. Liu et al. disclosed a one-step synthetic scheme toward cyclodextrin-modified
gold nanospheres (2-7 nm in diameter) by reduction of HAuCl4 using NaBH4 in the presence of
capping ligand per-6-thio--cyclodextrin.87 To improve the stability of this functionalized AuNP,
Li et al. modified Liu’s synthesis by replacing DMSO solvent with DMSO/H2O solvent
mixture.88 Beta-cyclodextrin (CD) is a cyclic oligosaccharide consisting of seven connected
glucose moieties that has a cone shape with a hydrophilic and a hydrophobic surface located on
the outer and inner sides, respectively. The hydrophilic outer surface provides water solubility
and the inner surface allows inclusion of small hydrophobic molecules through a host-guest
interaction driven by van der Waals forces. Beta-cyclodextrin modified AuNPs can be used as
multisite hosts for binding guest molecules of interest. The Kaifer group reported that CD
attached on the surface of AuNP can be used to control particle aggregation by accommodating
ferrocene derivative or ferrocene dimer89 and their noncovalent binding with CD was later
confirmed by measuring
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Figure 3-1. Synthetic scheme of thiolated -CD (7) functionalized AuNP loaded with Pt(IV)
complex 4.

voltammetric response.87 Li et al. developed a fluorescent assay for detecting naphthol isomers
using fluorescence dye-incorporated CD functionalized gold nanoparticle though the host-guest
interaction between CD and naphthol.88 The Shen group constructed a nanoenzyme system, a
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supramolecular assembly of the copper complex of triethylnetetramine-adamantane and CD
covalently bound to the surface of AuNP, to catalyze hydrolysis of an active ester 4,4’dinitrodiphenyl carbonate.90 Kim and colleagues reported on the therapeutic application of CDAuNP for delivery of an anticancer drug -lapachone by efficient noncovalent encapsulation of
the drug into CD.91
In this work, a Pt(IV) complex, 1-adamantanemethylamine-Pt(IV) (4, Figure 3-1), which
is a potential prodrug of the Pt(II) anticancer agent cisplatin is loaded onto CD modified AuNP
through host-guest interaction. The average number of complex 4 molecules loaded onto one
AuNP has been estimated and the cytotoxicity studies of the loaded delivery vehicle 6 toward
human neuroblastoma cell line (SK-N-SH) show inhibition to cell growth. The binding between
CD and 4 was investigated using 1H NMR titration. We also determined the cytotoxicity of the
inclusion complex 4-CD, toward SK-N-SH cells and, using agarose gel electrophoresis, studied
the ability of the ascorbic acid reduction product of 4-CD to bind to and unwind pBR322 DNA.
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3.2. Materials and Methods

3.2.1 Instrumentation

Mass spectra were obtained using an FTICR-MS with an Apollo II ion source (COSMIC
Lab, Norfolk, VA). Optical images of cells under white light illumination were obtained using a
Leica DMI 4000 B microscope with a Leica DFC 340 FX digital firewire camera system
(Syracuse Biomaterials Institute). Inductively coupled plasma mass spectrometry (ICP-MS) data
were obtained using a Perkin Elmer Elan DRC-e (SUNY College of Environmental Science and
Forestry). One dimensional 1H NMR spectra were obtained using a Bruker Avance 300 MHz
spectrometer at room temperature using a 5 mm probe. The proton resonance at 2.50 ppm, due to
a small amount of the protonated form of DMSO in d6-DMSO, was used as the internal chemical
shift standard.

3.2.2 Synthesis of 1-adamantanemethylamine-Pt(IV) Conjugate (4)

The conjugate Pt-AD, 4, was synthesized by adding 1-adamatanemethylamine (18.2 mg,
110 µmol), 3 (43.4 mg, 100 µmol)92, N-hydroxysuccinimide (12.7 mg, 110 µmol) and 1-ethyl-3(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 23.0 mg, 120 µmol) to anhydrous
DMSO (0.6 mL) and stirring the resulting solution at room temperature for 24h. The volume of
the solution was reduced in vacuo to produce bright yellow oil which was washed with ~ 10 ml
diethyl ether. After removal of the diethyl ether, ~ 5 ml of water was added which produced a
light yellow precipitate. The product was collected by filtration, washed with ice cold diethyl
ether and dried in vacuo. Yield: 57.2%. Mass spectrum of Pt-AD, 4 (1:1 THF:MeOH with NaCl)
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expected m/z of (C15H29N3O4Cl12Pt) Na+ = 603.1, observed m/e = 603.1. 1H NMR (300 MHz,
DMSO-d6): δ 7.66 (t, 1H, NH), δ 5.95 (m, 6H, 2 × NH3), δ 2.75 (d, 2H, CH2), δ 2.35 (q, 4H, 2 ×
CH2), δ 2.16 (s, 3H, 3 × CH adamantane) δ 1.63 (q, 6H, 3 × CH2 adamantane), δ 1.41 (s, 6H, 3 ×
CH2 adamantane).

3.2.3 Synthesis of Per-6-iodo--cyclodextrin
This compound was prepared as previously reported by Defaye and Gadelle.93 To a
stirred solution of triphenylphospane (21 g, 80 mmol) and iodine (2.02g, 80 mmol) in 80 mL
DMF was added CD (4.32 g, 3.8 mmol). The solution mixture was stirred at 80 °C for 19 h and
then concentrated to half of the volume under vacuum. The pH was adjusted by adding 3 M
sodium methoxide in methanol to 9-10 with simultaneous cooling. The solution was then kept at
room temperature for 30 min to destroy the formate esters formed. It was thereafter poured into
150 mL ice water to bring out a light brown precipitate which was collected by filtration. Yield:
73.1%. 1H NMR (300 MHz, d6-DMSO) δ = 3.24-3.47 (m, 21 H), 3.56-3.68 (m, 14 H), 3.80 (bd,
7 H), 4.99 (d, 7 H), 5.94 (d, 7 H), 6.06 (d, 7 H).

3.2.4 Synthesis of Per-6-thio--cyclodextrin (7)
This compound was prepared as previously reported by Rojas et al.94 To a solution of
per-6-iodo--cyclodextrin (0.965 g, 0.48 mmol) dissolved in DMF (10 ml) was added thiourea
(0.301 g, 3.95 mmol). The reaction mixture was heated to 70 °C and stirred overnight under an
argon atmosphere. The DMF was then removed under reduced pressure to afford yellow oil and
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was dissolved in 50 mL of water. Sodium hydroxide (0.26 g, 6.5 mmol) was added and the
mixture was heated to a gentle reflux under an argon atmosphere for 1 h. The resulting
suspension was acidified with aqueous NaHSO4 to bring out a brown precipitate. The precipitate
was filtered and washed with distilled water and dried under vacuum to yield 3 (81.0%) as an
off-white powder. 1H NMR (300 MHz, DMSO-d6): δ = 2.14 (bd, 7 H), 2.73 (m, 7 H). 3.21 (bd, 7
H), 3.35 (m, 14 H), 3.64 (bd, 14 H), 4.93 (d, 7 H), 5.83 (s, 7 H,), 5.94 (d, 7 H). HRMS (in 1:1
THF:MeOH 0.1% FA w/ NaCl): expected m/e of (C4H12N2O5Cl2Pt)Na+ = 1269.2. Observed m/e
= 1269.2.
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3.2.5 Synthesis of Thiolated -cyclodextrin Functionalized Gold Nanoparticles (5)
The functionalized AuNP was prepared as previously reported using perthiolated cyclodextrin as capping molecules.88 A solution of 48 mL DMSO containing 90 mg of NaBH4
(2.4 mmol) and 24.0 mg (0.019 mmol) of thiolated -cyclodextrin was added to a solution of 60
mL DMSO/H2O 4/1 containing 12.2mg (0.036 mmol) of HAuCl4. The reaction solution was
stirred at room temperature for 24 h. 96 mL of CH3CN was added to bring out precipitate which
was collected by centrifugation. The precipitate was first washed with 50 mL of mixed solvents
CH3CN and DMSO (1:1 v/v), the precipitate was isolated by centrifugation and washed again
with and 50 mL of ethanol. The precipitate was isolated by centrifugation and dried in vacuo.
The dried solid was taken up in 0.2 mL of H2O and solution was kept at room temperature for 30
min before adding 0.6 mL of CH3CN which induced precipitation of purified 5. The CD-capped
AuNP was collected by centrifugation and dried in vacuo overnight to obtain 10.7 mg dried
product. UV-Vis spectrum of the product in aqueous solution has an absorption peak at 515 nm.

3.2.6 Synthesis of Thiolated -cyclodextrin Functionalized Gold Nanoparticles Loaded with
1-adamantanemethylamine-Pt(IV) Conjugate (6)
To a solution of 0.75 mg of 4 (1.29×10-3 mmol), dissolved in 0.4 mL DMSO was added a
solution of 6.5 mg of 5 (1.29×10-3 mmol of gold-attached CD), dissolved in 0.1 mL H2O. The
reaction mixture was stirred overnight at room temperature following which time, 1.5 mL of
CH3CN was added to induce precipitation of 4 which was collected by centrifugation. The
precipitate was washed with 2 mL of CH3CN and DMSO (3:1 v/v), washed a second time with 1
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mL of ethanol, and the inclusion complex (4.0 mg) was isolated by centrifugation and dried
overnight in vacuo. The weight percentage of Pt in 4 (2.50 %) was obtained through ICP-MS
analysis. UV-Vis spectrum of the product in aqueous solution has an absorption peak at 515 nm.

3.2.7 UV-visible Absorption Spectra of 5 and 6

Cary 50 UV-vis spectrophotometer was utilized, with baseline correction in the region
200-800 nm. Aqueous solution of AuNP were prepared and tested in a cuvette with a 1 cm path
length.

3.2.8 Thermogravimetric Analysis (TGA) of Thiolated -cyclodextrin Functionalized Gold
Nanoparticles

TGA was carried out on a TGAQ500 by raising the temperature of the sample at a rate of
5 °C/min from room temperature to 100 °C. The temperature is held at 100 °C for 30 min to
eliminate water contained in the sample. Then the temperature was further increased to 200 °C at
the same rate and held for 1 hour to eliminate DMSO followed by a temperature increase up to
800 °C at 5 °C/min.

3.2.9 Transmission Electron Microscopy (TEM) of 5 and 6
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TEM measurements were performed on a JEOL 2000EX operated at 120 kV with a
tungsten filament (SUNY College of Environmental Science and Forestry, Syracuse, NY). The
diameters of AuNP 5 and 6 were calculated using ImageJ software on populations >100 particles
(counts).

3.2.10 1H NMR Studies of Adamantane Derivatives and 4-CD Inclusion Complex
One dimensional 1H NMR was obtained using a Bruker Avance 300 MHz spectrometer
at room temperature. A series of spectra with various r = [4]/[CD] were collected in solvent
mixture of d6-DMSO/D2O 4/1, and the chemical shift of protons on HA, HB1, HB2 and HC was
plotted against r (Figure 3-6). Complex 4 was first dissolved in d6-DMSO 0.48 mL to which 0.12
mL D2O was added, the final concentration of 4 was 16.7 mM. To this solution, by repeatedly
adding CD, measurements with increasing r values of 0.2, 0.4, 0.6, 0.8, 1.0, 1.5 and 2.0 were
made. A spectrum was collected 2 h after each addition to allow equilibrium of binding. 1H
NMR of 4 and two other admantane derivatives, 1-adamantanemethylamine and 1adamantanemethanol at various concentrations was tested in d6-DMSO/D2O 4/1 (Figures 3-8, 9
and 10). The d6-DMSO proton impurity signal at 2.50 ppm is used as internal standard.

3.2.11 Cytotoxicity Study of 4-CD Inclusion Complex toward Neuroblastoma Cells
(Compared with Cisplatin)

The studies involving human neuroblastoma (SK-N-SH) cells were carried out under
standard conditions as previously reported.95 The studies involving human neuroblastoma (SK46

N-SH) cells were carried out under standard conditions in a humidified, 37 °C, 5 % CO2
atmosphere in an incubator. The culture medium used for SK-N-SH cells was Eagle's minimum
essential medium (EMEM) to which had been added 10 % Fetal Calf Serum (FCS), 100 µg/mL
streptomycin, 100 IU/mL penicillin and 2.0 mM L-glutamine. Four solutions of Pt complex in
medium having Pt concentrations 2, 5, 10 and 20 µM were prepared by dissolving a weighed
amount of 4 or cisplatin. Complex 4 was first dissolved in 0.2 ml of DMSO which was diluted
with an aqueous solution of CD to give a final H2O-DMSO solution with [4]/[CD] = 0.5 and
DMSO, 0.4% (v/v). A stoichiometric excess of CD was used to drive the equilibrium in favor
of the inclusion complex. To each of 60 wells (6 groups of 10 wells each) in the central portions
of four 96-well microplates were added: medium alone containing no cells, Group 1, and
medium containing 5×104 cells/mL, Groups 2-6. The cells were allowed to grow for 24 h
reaching ~ 30% confluency after which time the medium was removed and replaced with 100 µL
of medium containing compound having concentrations of 0, 2, 5, 10, and 20 µM Pt for Groups
2-6, respectively. After a 72 h exposure time, the medium in the wells containing cells was
removed and replaced and washed twice with fresh medium. The number of live cells was
determined using the CCK-8 assay (Dojindo Molecular Technologies, Inc. Gaithersburg, MD)
according to the specified protocol and percent inhibitions determined as previously described 95.

3.2.12 DNA Capture-Gel Electrophoresis Experiments of 4-CD Inclusion Complex
The DNA binding studies were done in a total volume of 20 l containing 38.5 M base
pairs pBR322 DNA and 12 mM pH 7.4 HEPES buffer with 0.4% DMSO v/v. The final
concentration of 4 was in the range of 2.5-60 M while the final concentrations of CD was in
the range 5-120 M with, [4]/[CD] = 0.5. Ascorbic acid (final concentration 50 M) was used
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as the reducing agent for the Pt(IV) complex. The inclusion complex 4-CD, was first dissolved
in 0.1 ml DMSO followed by the addition of 24.9 ml of HEPES buffer to give a final aqueous
solution containing 0.4% DMSO v/v. Appropriate volumes of stock solutions were added to the
solutions containing the buffer and DNA to give the final concentrations in the reaction solutions
containing DNA stated above. The values of r, where, r = [4]/[DNA-bp], in the reaction
solutions are given in the captions of figures. The samples were incubated at 37 oC for 24 h in
sealed Eppendorf tubes and electrophoresis/analysis carried out as previously reported. The
percent inhibition of cell growth was calculated using the Equation (1), where %I is the percent
inhibition, At is the absorbance of wells with cells containing culture medium + Pt complex, Acis
the absorbance of wells with cells and culture medium, and Am is the absorbance of wells without
cells but with culture medium.

%I = 100 ×

(1)

3.2.13 Cytotoxicity Study of 6 toward Neuroblastoma Cells (Compared with Cisplatin)

The studies involving human neuroblastoma (SK-N-SH) cells were carried out under the
same conditions as stated in 3.2.12. Four solutions of the complex in medium having Pt
concentrations, 2, 5, 10 and 20 µM were prepared by dissolving a weighed amount of delivery
system 6 or cisplatin. To each of 60 wells, 6 groups of 10 wells each, in the central portions of
four 96-well microplates were added, medium alone containing no cells, Group 1, and medium
containing 5×104 cells/mL, Groups 2-6. The cells were allowed to grow for 24 h reaching ~30%
confluency after which time the medium was removed and replaced with 100 µL of medium
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containing compound having concentrations of 0, 2, 5, 10, and 20 µM Pt for Groups 2-6,
respectively. After 72h exposure time, the medium in the wells containing cells was removed and
replaced and washed twice with fresh medium. The number of live cells was determined using
the CCK-8 assay according to the specified protocol. The percent inhibition of cell growth was
calculated using the Equation (1).
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3.3 Results
Thiolated CD, 7, was synthesized following literature method94 and characterized using
1

H NMR and mass spectrometry. Gold nanoparticles capped with 3 were synthesized through a

one-step reaction by reducing HAuCl4 using NaBH4 in the presence of 7 in DMSO/H2O solvent
mixture as reported by Li et al.88 UV-Vis spectrum of 5 shows a surface plasmon absorption
peak located at 515 nm (Figure 3-2). The size of the AuNPs is 4.7 ± 1.1 nm in diameter which is
determined based on transmission electron microscopy (TEM) image (Figure 3-3).
Thermogravimetric analysis (TGA) curve (Figure 3-4) of 5 shows a weight loss of 26.63% from
209.10 °C to 460.59 °C which is the weight percent of thiolated CD, and the weight percent of
Au is 64.67%.
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Figure 3-2. UV–vis absorption spectra of AuNP 5 and AuNP 6 aqueous solution.
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Figure 3-3. TEM images of 5 (a), 6 (b) and diameter histogram (c) and (d) of 1 and 2 based
calculation of >100 particles in TEM images respectively.
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Figure 3-4. TGA curve of AuNP 5, wt%(CD) = 26.63% and wt%(Au) = 64.67%.

Pt(IV) anticancer prodrug 4 is synthesized as previously reported96 and loaded onto
functionalized AuNP 5 at room temperature. UV-Vis spectra (Figure 3-2) of the delivery vehicle
before and after loading with 4 both have a peak at the wavelength of 515 nm, which indicates
the presence of gold nanoparticles (AuNPs) and no significant change in diameter due to the
loading. This expectation is confirmed by the results calculated based on TEM images (Figure 33) which shows insignificant change in diameter after the loading of 4. The weight percent of Pt
(2.50%) in the 4 loaded AuNP is achieved through inductively coupled plasma-mass
spectroscopy (ICP-MS).
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Figure 3-5. 1H NMR of 4 and CD (r = [CD]/[4]=0.2, [4] =16.7 mM) in d6-DMSO/D2O 4:1
(v/v). See Figure. 3-1 for chemical shift assignment.
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Figure 3-6. Chemical shift of 1H NMR of 4 and CD inclusion complex vs r, [4] = 16.7 mM. (a)
HA, (b) The average of HB1 and HB2, (c) HC.
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Figure 3-7. 1H NMR of 4 in d6-DMSO/D2O 4:1 (v/v). (a) 2 mM, (b) 40 mM.
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Figure 3-8. Chemical shift of 1H NMR of 4 as a function of concentration. (a) HA, (b) The
average of HB1 and HB2, (c) HC.
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1-adamantanemethylamine

Figure 3-9. Chemical shift of 1H NMR of 1-adamantanemethylamine as a function of
concentration. (a) HA, (b) The average of HB1 and HB2, (c) HC.
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1-adamantanemethanol

Figure 3-10. Chemical shift of 1H NMR of 1-adamantanemethanol as a function of
concentration. (a) HA, (b) The average of HB1 and HB2, (c) HC.
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The binding between CD and 4 is investigated through 1H NMR (Figure 3-5) in d6DMSO/D2O 4:1 (v/v). The chemical shift of signals of protons HA,HB1, HB2 and HC of 4 is
plotted against r, the concentration ratio of CD to 4. The chemical shift of protons on adamantyl
group (AD) increases with increasing r value (Figure 3-6) which indicates a deshielding effect
due to host-guest interaction. Analysis of these curves gives information about the stoichiometry.
To further investigate the stochiometry of the host-guest inclusion complex formed by CD and
4, 1H NMR spectra of Pt(IV)-adamantane 4 complex (Figure 3-7) and two other molecules with
admantyl group, 1-adamantanemethylamine and 1-adamantanemethanol (Figure 3-9, 3-10) at
various concentrations were collected at various concentrations were collected. In Figure 3-7, 1H
NMR peak broadening is observed at relatively high concentration (Figure 3-7) and there is a
general trend of chemical shift decreasing with increasing concentration for all three admantyl
molecules (Figures 3-8~10). This implies a change in the environment of protons at higher
concentrations.
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Figure 3-11. Percent inhibition vs. the concentration of Pt of 4-CD (open bar) and cisplatin (black bar)
toward SK-N-SH cells.

Figure 3-12. Ethidium bromide stained agarose gel of pBR322 DNA in the presence of the
inclusion complex of 4-CD, in pH 7.4 HEPES buffer with AsA as the reducing agent.

Figure 3-11 gives the results of the cytotoxicity of the inclusion complex, 4-CD and,
compared with cisplatin, toward human neuroblastoma (SK-N-SH) cell line. As shown in bar

60

graph, inclusion complex inhibits the growth of the cell population by ~70%, versus ~ 98% for
cisplatin, at a Pt concentration of 20 M. Therefore the inclusion complex is less toxic to the
cells than is cisplatin. Using pBR322 DNA to capture the platinum Pt(II) product formed when the 4CD is reduced by AsA (Figure 3-12), closed circular Form I DNA shows a biphasic mobility pattern
which is consistent with the formation of the 1, 2 intrastrand crosslink 31.

Untreated

Treated

Scale Bar = 100 m
Figure 3-13. Microscope images of untreated SK-N-SH cells (a and d) and cells treated with 6
(20 M Pt) for 24 h (b and c) and 72 h (e and f). The dark spots in (b) and (c) show the
aggregation formed by internalized AuNPs.
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Figure 3-14. %Inhibition vs concentration of Pt of 6 (in black) and cisplatin (in grey) after 72 h
incubation for different concentrations of 6 and cisplatin.

Cytotoxicity of the constructed the delivery system (6) is investigated toward human
neuroblastoma cell line SK-N-SH. The cells were exposed to the delivery system and cisplatin
respectively for 72 h. As shown in Figure 3-13, the areas in frames show an example of
accumulations of AuNP in SK-N-SH cells with 24 and 48 h exposure time at 20 M Pt
concentration, and there are less cells in the delivery system treated group than the untreated
control group with healthy cells. It is illustrated in Figure 3-14 that the delivery vehicle has a
percent inhibition up to ~70% on the growth of SK-N-SH cells after 72 h exposure time at a Pt
concentration of 20 M and the percent inhibition is dose dependent. However, the percent
inhibition is lower than cisplatin as the Pt(IV) conjugate might not be completely reduced.
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3.4 Discussion
The ultimate goal of this work is to construct a delivery system to transport drugs like
complex 4 through host-guest interaction; therefore it is important to investigate the amount of
drug molecules that can be loaded onto the vehicle. To reveal the delivery capacity of the vehicle
5 through host-guest interaction pertaining to CD, we estimated the average number (n) of
attached CD molecules per AuNP using equation (2)97 and (3), where N is the average number
of gold atoms per AuNP, ρ is the density for fcc gold (19.3 g/cm3), D is the average core
diameter of the particles (nm), M is the atomic weight of gold (197 g/mol) and M’ is the
molecular weight of thiolated CD (1240 g/mol). Based on the experimental data from TEM
(Figure 3-3) and TGA (Figure 3- 4), D = 4.7 nm, wt%(βCD) = 26.63% and wt%(Au) = 64.67%,
therefore the calculated value of n is ~210.

(2)

n=

= 4.91 D3

(3)

The modified CD (7) can be conjugated to AuNP surface by a maximum of seven SAu covalent bonds. Assuming thiolated CD are close packed and form a monolayer of coating
on the surface of the AuNP, the theoretical maximum number of cyclodextrins per AuNP could
be estimated using equation (4), where SAu is the surface area of AuNP (nm2), SCD is the surface
area occupied by the wider opening of close packed CD (nm2) and d is the van der Waals
surface diameter of the larger opening of CD which has a value of 1.54 nm. As n is roughly
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estimated in this work, calculating the number of CD molecules forming a monolayer using the
surface diameter of either the smaller or larger end, would not lead to significant variation. By
inserting the experimental data, the result of this maximum number is ~34 which is much lower
than the number calculated (~210) using the experimental data. As workup procedure in
atmosphere is involved, we proposed a mechanism for binding: on the surface of AuNP,
disulfide bonds are formed between thiol βCD molecules so that a portion of the βCD molecules
are not directly attached to the surface of AuNP through Au-S bond as shown in Figure 3-1.

=

= 3.62

(4)

As it is possible that the βCD binding sites on the surface of AuNP are not fully
occupied by 7, Equation (5) is used to estimate the average number (n’) of 4 loaded onto one
AuNP, where M” is the atomic weight of Pt (195.08g/mol). Based on ICP-MS result, wt%(Pt) is
2.50%, therefore the value of n’ is ~125, which means ~60% of cyclodextrin sites on AuNP are
loaded with complex 4.

n’ =

= 31.20 D3

(5)

To further study the binding between 4 and 7, 1H NMR titration of 4 with βCD has
been conducted in d6-DMSO/D2O 4:1 (v/v). This part of work was done with great help from Dr.
Jerry Goodisman. As shown in Figure 3-6, with fixed concentration of 4 (16.7 mM), chemical
shift of protons on AD increases with higher r value (r = [CD]/[4]) indicating a deshielding
effect due to host-guest interaction. As it is commonly accepted that CD and adamantane
derivatives form inclusion complexes at a ratio of 1:1,98 we calculated the binding constant of
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CD and 4 based on 1:1 stochiometry. From the chemical shift data for the protons on HA, HB1,
HB2 and HC, the calculated binding constants are 82.2±19.7 M-1, 16.5±6.4 M-1 and 5.09±1.71 M1

, respectively, which are very inconsistent (Table 3-1). Therefore it appears that the 1:1 binding

model does not fit in this case.
As observed in Figure 3-7(a), 1H NMR signals of protons on HB1 and HB2 of
complex 4 with a concentration of 2 mM is a clear quartet while at higher concentration (40 mM,
Figure 3-7), the peak broadened and as shown in Figure 3-7(b), the chemical shift decreases with
increasing concentration, which can be evidences of change in the environment of protons at
higher concentrations. Therefore, we proposed a model of binding of 4 to CD at 1:1 ratio with
formation of complex 4 dimers, (4)2, so that there are two equilibria in the system with K1 and K2
as equilibrium constants, shown in Equation (6) and (7).

CD + 4
4

K1
K2

CD-4

(6)

(4)2

(7)

The values of K2 and the maximum chemical shift changes are varied to minimize the meansquare deviation between experimental and theoretical chemical shifts. It is found that when the
value of K2 is 0.0002 M-1, the binding constants calculated based on protons on C2, C3 and C4
are consistent. The values are 49.7±20.9 M-1 77.4±18.7 M-1 and 38.3±17.5 M-1, respectively. As
the value of K2 is low (0.0002 M-1), the concentration of (4)2 at equilibrium would also be low
which is in accordance with the assumption that almost all the bound AD is a monomer.
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Binding Constant
(M-1)
HA
HB1, HB2
HC

1:1
82.2±19.7
16.5±6.4
5.09±1.71

1:1 AD dimerization model K1
(K2 = 0.0002 M-1)
77.4±18.7
38.3±17.5
49.7±20.9

Table 3-1. Binding constants of 4 and CD in d6-DMSO/D2O 80/20 at room temperature in 1:1
stoichiometry without and with formation of AD dimers.

To test the cytotoxicity of the constructed delivery system (6), human neuroblastoma
cell line SK-N-SH was chosen as the test system since Pt based antitumor complexes such as
cisplatin and carboplatin are used to treat childhood cancers including neuroblastoma.99-101 As
shown in Figure 3-13, accumulations of AuNP in SK-N-SH cells occurs within 24 h exposure
time at 20 M Pt concentration, and there are fewer cells in the delivery system treated group
than the untreated control group with healthy cells. The dark spots in cancer cells in Figure 313(c) shows the accumulation of AuNP in cells after 24 h exposure, while after 72 h exposure
shown in Figure 3-13(f), the cells have been destroyed and the obscure dark spots show the
release of AuNP from broken cells. Figure 3-14 shows that the delivery vehicle has a percent
inhibition up to ~70% on the growth of SK-N-SH cells after 72 h exposure time at a Pt
concentration of 20 M. The percent inhibition is dose dependent and lower than that of cisplatin
indicating the Pt(IV) conjugate might not be completely reduced. Earlier study by us has shown
than the two precursors of 4, c,t,c-[PtCl2(OH)2(NH3)2] and c,t,c[PtCl2(OH)(O2CCH2CH2CO2H)(NH3)2], can be reduced by bioavailable reducing agents ascorbic
acid or glutathione and unwind plasmid circular DNA.102 The anticancer activity of 4 could be
exerted by reducing agents in biological system; the reduction product Pt(II) complex then binds
with DNA strands to induce cell death.
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Using pBR322 DNA to capture the platinum Pt(II) product formed when the 4-CD is
reduced by AsA, closed circular Form I DNA shows a biphasic mobility pattern which is
consistent with the formation of the 1, 2 intrastrand crosslink 31. When r increases, mobility of
Form I DNA first decreases and then increases with co-migration of both Form I and Form II
DNA at some value of r, in this case occurring at r = 0.52, which is a hallmark of the gel pattern
for the cisplatin-produced 1, 2 intrastrand crosslink. While the amount of platinum entering the
cells for either agent is unknown, the cytotoxic effects of the Pt(IV) compound are very likely
dependent on its ability to be reduced to a more reactive Pt(II) complex. As discussed above, 3,
which has the same donor ligands as 4 and its inclusion complex, 4-CD, can be reduced by
either AsA or GSH, with the former reducing agent producing cisplatin and the latter producing a
Pt(II) complex of unknown structure. Since there is no AsA and only a very small amount of
GSH, ~ 3 M, in the culture medium, it appears that the site of reduction of the inclusion
complex is the cytosol of the neuroblastoma cells where the concentrations of AsA and GSH are,
~ 1 and ~ 2 mM, respectively. Once the Pt(IV) ion in the inclusion complex is reduced to Pt(II)
in the cytosol, the product(s) could bind to proteins and/or DNA causing the cell to enter into
apoptosis and die.
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3.5 Conclusions
Gold nanoparticles (AuNPs) coated with per-6-thio-β-cyclodextrin, a hepta-thiol
ligand, were synthesized as a drug delivery vehicle for a Pt(IV) complex, 1adamantanemethylamine-Pt(IV) (4), which is a potential prodrug of the Pt(II) anticancer agent
cisplatin. It is estimated that an average of 210 hepta-thiol ligands are bound to the surface of the
particle. After loading the surface of the thiolated β-cyclodextrin modified AuNPs with 4 which
binds through host-guest interaction, chemical analysis shows that ~125 Pt (IV) conjugates are
bound to the particle. The results of cytotoxicity studies show that the loaded delivery vehicle
inhibits the growth of human neuroblastoma cells. Beta cyclodextrin facilitates the aqueous
solubility of complex 4 through a host-guest interaction and the inclusion complex formed shows
inhibition on the growth of SK-N-SH cells but it is less toxic than cisplatin. Agarose gel
electrophoresis indicates that reduction of 4-CD by AsA in the presence of pBR322 DNA
results in the formation of platinum-DNA, 1, 2 intrastrand crosslinks consistent with cisplatin
being formed in the reaction.
The binding of complex 4 and β-cyclodextrin is also investigated using 1H NMR, and
a model with a 1:1 stoichiometry with formation of adamantane dimers is proposed.
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4.2 Cytotoxicity of Cu(II) And Zn(II) 2,2’-Bipyridyl Complexes: Dependence of IC50 on
Recovery Time
4.1. Introduction
Copper in its ionic forms plays an important role in various proteins and metallo enzymes
in biological systems.103 Since free aquated copper is toxic to cells, nature has developed a
sophisticated mechanism for transporting the ion from its ingestion in the food supply to its
ultimate incorporation in critical biological components in the cell. Imbalanced copper levels in
the body lead to abnormal conditions which include Menkes disease, the neurodegenerative
genetic disorder. This disease is a childhood disorder which is characterized by reduced
absorption of copper and results in delayed development, mental retardation and early
mortality.31, 104 In contrast, Wilson’s disease, which can be Parkinson-like in nature, is
characterized by an excess of copper in the body and leads to reduced hepatic ability and/or
neurological problems. Copper ions are also important for blood vessel development in tumors
and the ion is believed to contribute to the growth, invasion and metastasis of cancer.105
Dwyer and coworkers reported that the Cu+2 complex of 3,4,7,8-tetramethyl-1, 10phenanthroline inhibits the growth of Land-schuetz ascites tumor in 1965.106 Thereafter, the anticancer properties of many copper complexes containing, 1, 10 phenanthroline, (o-phen) and
related ligands have been actively investigated.105, 107-110 Although the mechanism of the anticancer activity of these complexes is not known, it is possible that the compounds bind directly
to target molecules in the cell or participate in redox chemistry that produces radicals that
damage biomolecules in the cell. In 2009, Dou, Verani, and their coworkers synthesized a group
of Cu+2 complexes containing asymmetric tridentate donor ligands that induce apoptosis in C4-
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2B and PC-3 human prostate cancer cells.105, 111 Studies of mechanism with the compounds show
that they inhibit the chymotrypsin-like activity of the 20S proteasome. This mechanism of
inhibition makes them similar to the anticancer drug bortezomib, which is used for treating
multiple myeloma. The Casiopeínas are a group of Cu+2 mixed-ligand antineoplastic agents
which contain 1, 10-phenanthroline or 2, 2’-bipyridine (bpy) and other bidentate ligands.112-114 It
is reported that these compounds exhibit cytotoxicity, genotoxicity and antitumor effects but
their mode of action is presently unknown. Earlier Koiri et al., reported that the complexes,
M(bpy)(Ac)2•H2O, where M = Cu(II) and Zn(II), bpy = 2,2’-bipyridine and Ac = CH3CO2 bind
to purified lactate dehydrogenase, LDH. Moreover, when solutions of the compounds are
perfused into mice, they are able to reduce the levels of LDH in tissues and organs.115 Since
inhibition of LDH blocks the interconversion of NADH and NAD+, a reaction that is critical for
cell survival, inhibiting the enzyme with small molecules could be a useful strategy for killing
cancer cells in chemotherapy.116-117

Figure 4-1. Structures of metal complexes 8-10
In this report we measured the percent inhibition, I, of Cu(bpy)(NCS)2, 8,
[Cu(bpy)2(H2O)](PF6)2, 9, and Zn(bpy)2(NCS)2, 10, toward neuroblastoma (SK-N-SH) and
ovarian cancer (OVCAR-3) cells as a function of time after the cells have been exposed to the
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metal complex, i.e., as a function of the recovery time, t. The study revealed that while surviving
cells previously exposed to the zinc complex divide normally during the recovery period,
surviving cells previously exposed to the copper complexes are slowed from dividing during the
recovery period. After deriving the relationship between I and t we show that the measured value
of IC50 for the two copper complexes strongly depends on t while IC50 for the zinc complex is
relatively independent of t. Since earlier reports by Sigman et al. that copper-phenanthroline
complexes can be activated to cleave DNA,118 we also studied the ability of the complexes to cut
closed circular pBR322 DNA in the presence of the biologically common reducing agent,
ascorbic acid.
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4.2. Materials and methods

4.2.1 Materials

Human neuroblastoma (SK-N-SH) cells and human ovarian carcinoma (OVCAR-3) cells
were purchased from the American Type Culture Collection (ATCC Number HTB-11 and HTB161). Minimum essential medium with Earle’s salts and L-glutamine (EMEM)(10-010), RPMI
1640, fetal calf serum (FCS), cell-stripper, and trypan blue stain, were from Mediatech
(Herndon, VA). The cell counting kits, CCK-F and CCK-8, which determine the number of live
cells in a population, were obtained from Dojindo Molecular Technologies, Inc. (Gaithersburg,
MD). Plasmid pBR322 was purchased from Invitrogen Inc. (Carlsbad, CA). For the DNA
cleavage studies, HEPES, agarose, Trizma base, boric acid, EDTA, ascorbic acid were purchased
from Sigma-Aldrich (St. Louis, MO), the plasmid DNA (pBR322), 25 µg/µl, was from
Invitrogen (Carlsbad, CA).

4.2.2 Cytotoxicity Studies

The studies involving human neuroblastoma (SK-N-SH) cells and human ovarian
carcinoma (OVCAR-3) cells were carried out under standard conditions in a humidified, 37 °C, 5
% CO2 atmosphere in an incubator. The culture medium used for SK-N-SH cells was Eagle's
minimum essential medium (EMEM) to which had been added 10 % Fetal Calf Serum (FCS),
100 µg/mL streptomycin, 100 IU/mL penicillin and 2.0 mM L-glutamine. The culture medium
used for OVCAR-3 was RPMI 1640 (Roswell Park Memorial Institute) to which had been
added 20 % Fetal Calf Serum (FCS), 100 µg/mL streptomycin, 100 IU/mL penicillin, 2.0 mM L-
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glutamine and 10 µg/mL insulin. Four solutions of the complex in medium having
concentrations, 250, 500, 1000, and 2000 µM were prepared by dissolving a weighed amount of
complex in 0.3 mL of DMSO followed by the addition 5.7 mL of culture medium to give the
indicated final compound and DMSO (5%) concentrations. To each of 60 wells, 6 groups of 10
wells each, in the central portions of four 96-well microplates were added, medium alone
containing no cells, Group 1, and medium containing 5×104 cells/mL, Groups 2-6. The cells
were allowed to grow for 24 h reaching ~30% confluency after which time the medium was
removed and replaced with 100 L of fresh medium containing 5 % DMSO, Group 2, or 100 L
of medium containing compound having concentrations of, 250, 500, 1000, and 2000 M for
Groups 3-6, respectively. After an exposure time to copper/zinc compound of 1 h, the medium in
the wells containing cells was removed and replaced with fresh medium and the cells were
allowed to recover for 2, 26, 50, and 74 h at the end of which time the number of live cells was
determined using the CCK-F assay according to the specified protocol. The CCK-F assay relies
on esterases in live cells to convert a precursor compound into a calcein dye the amount of which
can be quantitated by fluorescence. The viability of SK-N-SH cells was also determined using a
second method, the CCK-8 assay, following the same procedure. The CCK-8 assay relies on
dehydrogenases in live cells to convert a tetrazolium salt into formazan dye the amount of which
can be quantitated by absorption spectroscopy. The concentrations of copper/zinc complex used
were 25 M, 250 M, 2500 M.
The percent inhibition of 8-10 was calculated using the equation (8), where I is the
percent inhibition, AD is the absorbance or fluorescence of wells containing cells + culture
medium + 5 % DMSO, AT is the absorbance or fluorescence of wells with cells containing
culture medium + 5 % DMSO + the copper/zinc complex, AC is the absorbance or fluorescence
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of wells with cells and culture medium, and AM is the absorbance or fluorescence of wells
without cells but with culture medium.
 A  AD 
I  100   T

 AC  AM 

(8)

4.2.3 DNA Cleavage Studies by Agarose Gel Electrophoresis
Six solutions, 20 l each, in 10 mM HEPES buffer (pH 7.4) each containing various final
concentrations of 8 and 9 (1, 2, 4, 6, 8 and 10 µM) and 10 (10, 20, 30, 40, 50 and 60 µM) and
plasmid DNA (33.3 M base pairs) were prepared. Since stock solutions of the complex were
prepared in a manner analogous to those described for the cell studies, the reaction solutions also
contained 5 % DMSO. The reaction solutions, along with solutions containing DNA alone in 10
mM HEPES buffer with and without 5 % DMSO, were incubated at 37 oC for 30 min. After this
time a stock solution of ascorbic acid (final concentration, 1.0 mM) was added to the complexcontaining solutions and the resulting mixtures were incubated at 37 oC for an additional 30 min
to produce DNA strand cleavage. As a control DNA in buffer and 5% DMSO was incubated
with complex for 0.5 h in the absence of activator. Following incubation, the reaction mixtures
were quenched by rapid cooling using dry ice and 2.5 µl of a loading buffer containing 50 %
glycerol, 0.25 % bromphenol blue and 0.25 % xylene cyanol was added to each sample. An 8 µl
volume of each solution was loaded onto a 1 % (w/v) agarose gel in 0.5X (0.045 M Tris-borate
and 0.001 M EDTA) TBE buffer (pH 7.4) and electrophoresis was carried out at 100 V for 4 h.
The gel was exposed to a 5 x 10-5 % solution of ethidium bromide for 30 min and washed (de-
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stained) in distilled water for 15 min. An image of the gel was captured using a Kodak Gel Logic
100 imaging system.
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4.3 Results and Analysis
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Figure 4-2. Percent inhibition of cell growth vs. compound concentration on SK-N-SH cells. The
cells were exposed to a compound for 1 hour and incubated on separate plates for 2h, 26h, 50h
and 74h before measurement. Data collected from CCK-8 and CCK-F assays were represented
by squares and diamonds respectively. The curves were the best fits of equation (9) to the data
from CCK-F assays. First four panels, results for Cu(bpy)(NCS)2, 8, next four panels, results for
[Cu(bpy)2(H2O)2](PF6)2, 9, last four panels, results for Zn(bpy)2(NCS)2, 10.
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Figure 4-3. Percent inhibition of cell growth vs. compound concentration on OVCAR-3 cells.
The cells were exposed to a compound for 1 hour and incubated on separate plates for 2h, 26h,
50h and 74h before measurement. Data collected from CCK-F assays was represented by
diamonds. The curves were the best fits of equation (9) to the data from CCK-F assays. First
four panels, results for Cu(bpy)(NCS)2, 8; next four panels, results for [Cu(bpy)(H2O)2](PF6)2, 9,
last four panels, results for Zn(bpy)(NCS)2, 10.

The data analysis of this work was done with generous help from Dr. Jerrey Goodisman.
Figures 4-2 and 4-3 show the percent inhibition of SK-N-SH neuroblastoma cells and OVCAR-3
ovarian cancer cells by Cu(bpy)(NCS)2, 8, [Cu(bpy)2(H2O)](PF6)2, 9, and Zn(bpy)2(NCS)2, 10,
as functions of concentration for various recovery times. Either cancer cell line was exposed to
one of the metal complexes for one hour, after which the complex solution was removed and
replaced by fresh medium. The recovery time is the period after the removal of metal complex,
during which the cells were incubated. Cytotoxicity of complexes 8, 9 and 10 was investigated
with SK-N-SH cell line using both CCK-F and CCK-8 assays, and OVCAR-3 cell line using
CCK-F assay. CCK-8 is a colorimetric assay which is similar to but more sensitive than MTT
assay. CCK-8 relies on the conversion of a colorless tetrazolium salt into an optically detectable
formazan dye by dehydrogenases. Absorbance of controls and cell culture exposed to various
concentrations of complexes 8, 9 and 10 after different lengths of recovery time were read. Since
Cu(II) and Zn(II) bypyridyl complexes were reported to be inhibitors of lactate dehydrogenase
(LDH), we also tested the cytotoxicity of the metal complexes using CCK-F assay which is not
dependent on dehydrogenases. CCK-F is a fluorometric assay in which a fluorescent dye,
calcein, produced from Calcein-AM (3’,6’-di(O-acetyl)-2’,7’-bis[N,N-bis(carboxymethyl)aminomethyl]-fluorescein, tetraacetoxymethyl ester) by esterases inside live
cells is released to the culture medium and its concentration is proportional to the number of live
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cells. Therefore, the possible ability of complex 8, 9 and 10 to inhibit LDH would not influence
the result of CCK-F. Fluorescence of controls and cell culture exposed to various concentrations
of complex 8, 9 and 10 after different lengths of recovery time were read.
Based on data from CCK-8 assay, curves shown in Figures 4-2 and 4-3 are the best fits to
the function
I = 100(1  ec)

(9)

where I is the percent inhibition of cell growth,  is the molar inhibition parameter and c is the
concentration of metal complex. This function is selected based on the assumption that the
number of live cells increases exponentially. When the cells are not treated with 8-10, no
inhibition occurs while no matter how high concentration of 8-10 is applied, the percent
inhibition does not exceed 100. In (9), I is an exponential function of c and when c = 0, I = 0;
when c , I  100. The measured percent inhibition I is equal to
I = 100(1  Nt/Nu)

(10)

where Nt is the number of live cells in a microplate well treated with metal complex and Nu the
number of live cells in a well not treated with 8-10; Nt/Nu is obtained from the absorbance or
fluorescence according to (8). The dispersed data points represented by diamonds in Figures 1
and 2 were collected from CCK-F assay.
We suppose that without treating with metal complexes, cells in the control group
reproduce with growth constant k so, if the number of live cells at time 0 is No, the number of
live cells at time t (Nu) is Noekt. During the exposure period, if the metal complex only kills a
fraction of the cells, f, without affecting the health of the surviving cells, the number of live cells
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at time 0 (just after the exposure period) is (1  f)No and the number of live cells at time t (Nt) is
(1  f)Noekt. It is evident from (10) that I is always equal to 100f, independent of the recovery
time t.
It is expected that f depends on the concentration of drug used, c, becoming zero for c = 0
and approaching 1 for c  . A simple representation of this is: f = 1  exp(c), as used in
equation (9). When the percent inhibition of 50%, i.e. f is 0.5, the concentration c is equal to
ln(2)/, which is the value of IC50. This gives a single number for IC50 only in the simplest case,
when I depends on c but not on recovery time t. It is evident from the calculated IC50 values,
given in Table 4-1, as well as from the initial slopes in Figures 4-2 and 4-3, that this is not at all
the case for the copper complexes considered here.
The initial slopes of the plots almost always increase with the recovery time. The reason
is that the copper complexes have a long-lasting effect on the health of the surviving cells,
besides killing a fraction f of the cells during the time that the cells are exposed to the agent.
They have continual hindrance to division of the surviving cells after the agent is removed, i.e.,
during the recovery period. Therefore, simply measuring the IC50 by measuring f at one recovery
time may hide important information about this additional effect. If the effects of the drug are
long-lasting, so that the surviving cells are in less than perfect health, they will have a growth
rate k’ which is smaller than k. Then, assuming a fraction f of the original cells were killed, the
number of treated cells at time t is
Nt(t) = (1  f) Noek’t
with the percent inhibition
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I = 100

N o e kt  (1  f ) N o e k 't
= 100[1  (1  f)e(k’ k)t]
kt
Noe

(11)

Since k’ is smaller than k and f is not negative, the percent inhibition, I, will increase with t. For
a fixed value of t, we abbreviate e(k’ k)t by C(t). Then, inserting the concentration-dependence of
f, f = 1  exp(c), we have

I = 100[1  C(t) e

- c

]

(12)

There is possibility that C(t) depends on concentration c as well as on t. However, the limited
number of data points in the case of the metal complexes in this report (3 to 5 in each case) and
the relatively large experimental errors do not justify using a two-parameter function to fit the
data. Thus we have used (9) instead of (12) in Figures 4-2 and 4-3, corresponding to C = 1. If,
however, C(t) really decreases with t, the second term in (12) will be smaller for larger t, which
will appear as an increase in the value of  (molar inhibition parameter) with t.
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SK-N-SH cells

a

OVCAR-3 cells

Complex,
recovery time

, M1

r2

, M1

r2

IC50,M

8, 2 h

0.000148

0.699

4683

8, 2 h

0.000120

0.628

5776

8, 26 h

0.000190

0.490

3648

8, 26 h

0.000914

0.857

758

8, 50 h

0.000266

0.895

2606

8, 50 h

0.001227

0.880

565

8, 74 h

0.000645

0.956

1075

8, 74 h

0.004606

0.712

150

9, 2 h

0.000700

0.594

990

9, 2 h

0.000117

0.265

5924

9, 26 h

0.001419

0.723

488

9, 26 h

0.000803

0.924

863

9, 50 h

0.001728

0.745

401

9, 50 h

0.002144

0.940

323

9, 74 h

0.001840

0.782

377

9, 74 h

0.001221

0.679

568

10, 2 h

0.000493

0.978

1406

10, 2 h

0.000534

0.936

1298

10, 26 h

0.001238

0.865

560

10, 26 h

0.000676

0.862

1025

10, 50 h

0.001010

0.822

686

10, 50 h

0.000490

0.830

1415

10, 74 h

0.000873

0.818

794

10, 74 h

0.000463

0.798

1497

IC50,M Complex,
recovery
time

Cu(bpy)(NCS)2, 8, [Cu(bpy)2(H2O)](PF6)2, 9, and Zn(bpy)2(NCS)2, 10.

Table 4-1. Molar inhibition parameter, , and r-squared values for all complexes and recovery
times, derived from the results plotted in Figures 4-2 and 4-3.a
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It is apparent from the figures that the fits to (9) are good overall. This is shown by the
values of r2 (goodness of fit), which are calculated according to

 (I  I )
 (I  I )

cal 2
j

j

r2 = 1 

j

2

(13)

j

k

where Ij is the measured inhibition for the jth complex concentration,

I

is the mean value of Ij,

and I jcal the corresponding inhibition calculated according to (9). Table 4-1 shows r2 for all 24
conditions employed in this study, as well as the molar inhibition parameter  for each.
As shown above, by considering how the molar inhibition parameter  depends on recovery time
t, one can determine whether there are long-lasting, effects on the cells (in addition to the initial
cell kill produced by exposure to the agent). If, for example, the agent hinders cell division but
the cells remain competent to be detected as being alive with a standard cell assay,  will
increase with t. If there are no effects of the agent on the cells after the initial kill,  will be
constant or independent of t during the recovery period. In order to determine whether  depends
on t, we have performed linear fits on all six data sets given in Table 4-1. For 8 the slope is (7.8
 3.1)10–6 M-1 h-1 for SK-N-SH and (5.7  2.0)10–5 M-1 h-1for OVCAR-3, i.e. the slopes are
definitely positive. This indicates that, besides killing some cells during the 1 h exposure time,
compound 8 produces long-term effects, in that cells divide more slowly during the recovery
period. For 9, the slope is (1.6  0.4)10–6 M-1 h-1 for SK-N-SH and (1.9  1.4)10–5 M-1 h1

for OVCAR-3. Since these slopes are definitely positive, 9 also hinders cell division during the

recovery period. For 10, the slope is (3.8  6.6)10–6 M-1 h-1 for SK-N-SH and (–1.7  1.8)10–
6

M-1 h-1 for OVCAR-3, i.e., the slopes are essentially zero in both cases. Thus the zinc
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complex differs from the copper complexes in that the copper complexes hinder cell division
during recovery but the zinc complex, which also kills cells during the exposure period, does not
affect cell division during the recovery period.

Compound

Cells

8

SK-N-SH

Assay
CCK-F

CCK-8

9

OVCAR-3

CCK-F

SK-N-SH

CCK-F

CCK-8

10

OVCAR-3

CCK-F

SK-N-SH

CCK-F

CCK-8

OVCAR-3

CCK-F

Conc.,
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Table 4-2. Slopes with errors of plots of Nt/Nu vs. time for a fixed concentration of complex.a
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Figure 4-4. The ratio Nt/Nu is plotted against recovery time t for fixed concentration of agent,
where Nt = number of cells in treated population and Nu = number of cells in untreated
population. Nt and Nu were measured using the CCK-F assay. First six plots are for compound
8, next six for compound 9, last six for compound 10. For the copper compounds 8 and 9, Nt/Nu
decreases with t, but this is not the case for the zinc compound 10.

Figure 4-5. The ratio Nt/Nu is plotted against recovery time t for fixed concentration of agent,
where Nt = number of cells in treated population and Nu = number of cells in untreated
population. Nt and Nu were measured using the CCK-8 assay. First three plots are for complex
8, next three for complex 9, last three for complex 10. For the copper compounds 8 and 9, Nt/Nu
decreases with t, but this is not the case for the zinc compound 10.

There is evidence that IC50 may depend on recovery time if the agent being tested affects
the division rate of cells after exposure to the agent. In Figures 4-4 and 4-5 and Table 4-2, we
show directly the effect of recovery time t on the ratio of treated to non-treated cells, Nt/Nu; for a
fixed concentration of complex, Nt/Nu is plotted against t. If there are no effects on division,
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Nt/Nu will be independent of t, but if division is hindered due to exposure to the agent, Nt/Nu will
decrease with t. It may also happen that Nt/Nu increases with t, which means that the surviving
cells divide more rapidly than the untreated cells after exposure to the agent. Table 4-2 shows
the results of linear fits of Nt/Nu vs. t for fixed c of metal complex. For the copper compounds,
the slope is definitely negative (magnitude of slope greater than standard error) for both assays
and both cell types except for one case. For SK-N-SH cells with the CCK-8 assay and 25 M of
8, the slope is negative but its magnitude is less than the standard error, so that the slope is
statistically zero. It is clear that the two copper complexes diminish the reproductive capacity of
the cells which survive the initial exposure to the complex. For the zinc compound, 10, the
situation is quite different in that the slope is statistically zero in three cases, statistically negative
in only one case, and statistically positive in five cases. This shows that the reproductive
capacity of the surviving cells which have been treated with the zinc complex is certainly not
diminished. In contrast, the metal complex may even enhance division.
We also compared the results of the two assays, CCK-8 and CCK-F, for neuroblastoma,
SK-N-SH cells. It is evident in Figure 4-2 that in 32 out of 36 points, the measured inhibition for
the CCK-8 assay is within one standard deviation of the curve obtained by fitting the inhibitions
measured using the CCK-F assay. The agreement suggests that both assays are detecting the
same number of live cells.
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(a)

(b)

(c)

(d)

Figure 4-6. Agarose gel electrophoresis images of 8 (a), 9 (b) and 10 (c) cleavage of pBR322
DNA in the presence of the activator, ascorbic acid (1 mM, 0.5 h), and a control group (d)
showing the effects of the metal complexes alone on DNA in the absence of the activator. The
studies were done in 1 mM HEPES buffer with 5% (v/v) DMSO, pH 7.4 at 37 oC. In (a)-(c), lane
1: DNA alone, lane 2: DNA plus 5 % DMSO, lane 3: DNA with ascorbic acid, no complex. (a)
For lanes 4-6, which contained ascorbic acid, the lane numbers and [8]/[DNA-base pairs] are: 4,
0.03; 5, 0.06; 6, 0.12; 7, 0.18; 8, 0.24; 9, 0.30. (b) For lanes 4-6, which containe ascorbic acid,
the lane numbers and [9]/[DNA-base pairs] are: 4, 0.3; 5, 0.6; 6, 1.2; 7, 1.8; 8, 2.4; 9, 3.0. (c) For
lanes 4-6, which contained ascorbic acid, the lane numbers and [10]/[DNA-base pairs] are: 4,
0.3; 5, 0.6; 6, 0.9; 7, 1.2; 8, 1.5; 9, 1.8. A control group without ascorbic acid is shown in (d).
Lane 1: DNA alone, lane 2: DNA plus 5 % DMSO. For lanes 3 and 4, [8]/[DNA-base pairs] are
0.15 and 0.30; for lanes 5 and 6, [9]/[DNA-base pairs] are 0.3 and 3.0; for lanes 7 and 8,
[10]/[DNA-base pairs] are 0.3 and 3.0. After electrophoresis, the DNA was stained with
ethidium bromide.

Since copper-o-phenanthroline complexes are known to cleave DNA in the presence of
activating agents,118 the ability of the 2, 2’-bipyridine compounds 8-10 to cleave the closed
circular pBR322 DNA in the presence and absence of ascorbate was also studied. As is evident
from Figure 4-6, 8 and 9 can be activated by ascorbate to cut closed circular DNA, eventually
reducing the plasmid to low molecular weight fragments which appear as an ethidium bromide-
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stained streak in the gel. This behavior contrasts with that of Zn(bpy)2(NCS)2, 10, Figure 4-6 (c),
which produces no DNA cleavage in the presence of ascorbate. In the absence of ascorbic acid
none of the complexes produced DNA cleavage, Figure 4-6 (d).
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4. 4 Discussion
In this work, the correlations of cytotoxic properties and recovery time, t, is investigated
with three metal complexes: Cu(bpy)(NCS)2, 8, [Cu(bpy)2(H2O)](PF6)2, 9, and Zn(bpy)2(NCS)2,
10. Structurally, 8 is a 4-coordinate approximately square planar Cu(II) complex with N-bonded
thiocyanate ligands, 9 is a 5-coordinate, trigonal bipyramidal Cu(II) complex with a coordinated
water molecule and 10 is a 6-coordinate approximately octahedral Zn(II) compound with two Nbonded thiocyanate ligands (Figure 4-1). The cytotoxicities of the metal complexes toward
neuroblastoma, SK-N-SH and ovarian cancer, OVCAR-3, were measured using two standard
assays to detect the number of live cells. To reveal long lasting effects that the complexes may
have on the cells after 1 h exposure, the number of living cells was determined at different
recovery times. The results show that the copper complexes, 8 and 9, hinder the cell growth,
while the zinc complex, 10, has no, or possibly a weak stimulating, effect on cell division during
the recovery period (Figures 4-2 and 4-3 and Table 4-1). As shown, IC50 is equal to ln(2)/, and
 is the molar inhibition parameter. Since can depend on recovery time, reporting IC50 for a
single recovery time can hide important information concerning the health of the cell population
after exposure to the toxin.
In this case the hidden information is that the copper complexes, 8 and 9, not only kill
some of the SK-N-SH and OVCAR-3 cells during the 1 h exposure period, but also have a
longer-lasting effect on the surviving cells, causing them to divide more slowly than healthy cells
in a control group. This is shown in the slopes of plots of Nt/Nu vs. recovery time t (Figures 4-4
and 4-5 and Table 4-2). The larger the value of t, the greater the percent inhibition at a certain
concentration of compound. Therefore, the apparent value of IC50 decreases with larger t values,
i.e., the compounds appear more cytotoxic for larger t. As shown in Table 4-1, the IC50 of the
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two copper complexes 8 and 9 is lowered by more than an order of magnitude when the recovery
time is increased from 2 h to 74 h for both cell lines studied. Structurally, 8 contains one 2,2’bipyridine ligand and the compound is uncharged while 9 has two 2,2’-bypyridine ligands and
the complex is a divalent cation (Figure 4-1). Interestingly, 9 is apparently more toxic than 8
toward neuroblastoma cells but there is no apparent difference in the toxicity of the compounds
toward the ovarian cancer cell line (Table 4-1). However, additional study will be required to
discover if this difference in cytotoxicity toward the two cell lines is related to the charge on the
compounds and/or the number of 2,2’-bipyridine ligands attached to the metal ion. On the
contrast, as shown in Table 4-1, the zinc complex 10 does not show a decrease in IC50 with t and
may even enhance the ability of cells to divide at certain concentrations.
Recovery time has been noted to be important in Murine leukemia L1210 cells treated
with cisplatin, in that low concentrations of the drug caused the cells to be transiently arrested in
the G2 phase for about 3 days before this phase is bypassed and growth is resumed.63 In another
study, Bogdanovic et al. reported that cisplatin analogs containing sulfur carrier ligands affected
the growth of MCF7 human breast cancer cells during the recovery period64 and both inhibitory
and stimulatory effects on cell division were observed, depending on the platinum complex being
investigated. This makes the reported value of IC50 strongly dependent on the time (recovery
period) at which inhibition is measured.
Evidently, percent inhibition observed for cell growth depends not only on the
concentration of cytotoxic agent but also on the length of time that the cells are in contact with
the agent, i.e. the exposure time. It is believed that the relevant parameter is the AUC, the Area
Under the Curve giving drug concentration vs. time.31 If this curve resembles a rectangle, AUC =
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concentration  exposure time. In a study involving Jurkat cells and cisplatin,119 the percent
viability of the cell population measured 24 h after exposure to the drug correlated inversely with
AUC, where AUC was calculated as the product of exposure time and drug concentration. If the
amount of cell death does depend only on AUC, one can obtain the same information about
inhibition using any convenient exposure time. In this study, we have used 1 h in the
experiments. In a very crude way this approximates a short i.v. administration of cisplatin and
its rapid clearance from blood, t1/2 ~0.5 h.31
While this study provides no detailed mechanistic information on how the 2, 2’bipyridine complexes are able to kill neuroblastoma and ovarian cancer cells, the facts that (a) all
of the complexes have the bpy ligand and (b) only the copper complexes have long-lasting
effects during recovery period suggests that the coordinated copper ion is important in slowing
the division of and killing cells. Since it is known that Cu(II) in the biological system can
facilitate the production of hydroxyl radical, hydrogen peroxide, and superoxide, collectively
referred to as ROS,31, 118, 120 it is possible that 8 and 9 induce ROS which damage biological
molecules in the cell. This mechanism, which may produce the damage observed to biological
molecules in Alzheimer’s Disease, requires a reducing agent and molecular oxygen, and the
copper ion must change its oxidation state.
Since DNA is well known as an important target for anticancer agents, we investigated
the ability of 8-10 to cleave closed circular pBR322 DNA. Figure 5 (a) and (b) show that the two
copper compounds, 8 and 9, induce breakage of closed circular pBR322 DNA in the presence of
an excess of the common biological reducing agent ascorbic acid. The level of breakage is in a
manner which is dependent on the concentration of complex present in the medium. Since
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molecular oxygen was not excluded in the reaction, this observation is consistent with coppermediated damage to DNA through the production of ROS.31 However, in the case of the zinc
complex, 10, Figure 4-6 (c) shows that cannot break DNA under the same activating conditions.
Since Zn(II) cannot easily change its oxidation state, this observation is also consistent with 8
and 9 damaging DNA via a ROS-generating type mechanism. In the absence of ascorbic acid,
none of the complexes cut pBR322 DNA, Figure 4-6(d), which shows the reducing agent plays
an important role in the cleavage process.
Earlier it was suggested that lactate dehydrogenase, LDH, may be a biological target for
M(bpy)(Ac)2•H2O, where M = Cu(II) and Zn(II), bpy = 2,2’-bipyridine and Ac = CH3CO2
compounds which are similar in structure to 8-10.14 The CCK-8 cell assay used in this
investigation requires viable cellular dehydrogenases for reducing a tetrazolium salt to a
formazan dye while the CCK-F assay requires viable esterases for producing a detectable
fluorophore for quantitating the number of live cells. In view of the fact that both assays, within
error, yield the same number of live cells, it would seem that the killing mechanism used by
these compounds does not involve either esterases or dehydrogenases. Clearly additional work
will be needed to uncover the molecular mechanism by which these interesting compounds kill
cancer cells.
4. 5 Conclusions
In this work, the cytotoxicities of three compounds, Cu(bpy)(NCS)2, 8,
[Cu(bpy)2(H2O)](PF6)2, 9, and Zn(bpy)2(NCS)2, 10, toward neuroblastoma, SK-N-SH and
ovarian cancer, OVCAR-3, cells as a function of recovery time, t, was investigated using CCK-8
and CCK-F assays. Cells endured exposure to a metal complex for 1 h, after which the agent
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was removed and the number of live cells measured using two standard cell counting assays. For
the two copper complexes the results depend strongly on drug concentration and on the time
allowed to elapse between removal of the metal complex and the measurement of the number of
live cells in the population, i.e., the recovery time t, showing that the measured value of IC50
strongly depends on the recovery time. We suggest that when measuring the cytotoxicity of an
agent in a cell study it is important to measure the percent inhibition and IC50 at various recovery
times which will uncover the long-term effects of the toxin on the health of the cell population.
In contrast to the copper complexes, the zinc complex, 10, was only weakly cytotoxic and had
little or no effect on cell division during the recovery period.
The study also showed that, in the presence of ascorbate, Cu(bpy)(NCS)2, 8 and
[Cu(bpy)2(H2O)](PF6)2, 9, cleave closed circular pBR322 DNA while Zn(bpy)2(NCS)2, 10,
cannot induce DNA strand scission, an observation which is consistent with the redox inertness
of the Zn(II) ion in 10. Additional work will be needed to determine if DNA and/or proteins are
targets for these metal complexes in the cell.
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5. Appendix

Figure 5-1. IR spectrum of oxoplatin (2)
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Figure 5-2. 5Pt NMR spectrum of 3 in H2O/D2O (95/5). A solution of 10 mM potassium
hexachloroplatinate in H2O/D2O (95/5) was used as an external standard (0 ppm).
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Figure 5-3 1H NMR spectrum of 3 in d6-DMSO.
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Figure 5-4. 13C NMR spectrum of 3 in d6-DMSO.
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Figure 5-5. DEPT135 NMR spectrum of 3 in d6-DMSO.
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Figure 5-6. 1H NMR spectrum of 4 in d6-DMSO.
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Figure 5-7. 1H NMR spectrum of per-6-iodo--cyclodextrin in d6-DMSO.
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Figure 5-8. 1H NMR spectrum of 7 d6-DMSO.
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Figure 5-9. Mass spectrum of 3

Figure 5-10. Mass spectrum of 4
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Figure 5-11. Mass spectrum of 7
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Scale Bar = 100 m
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Figure 5-12. Microscope images of untreated SK-N-SH cells and cells treated with 6 (20 M Pt)
for 0 h (a and b), 24 h (c and d), 48 h (e and f), 72 h (before washing, g and h) and 72 h (after
washing, i and j)
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